https://trial.medpath.com/news/all-five-longitude-health-member-systems-join-as-design-partners-for-cell-and-gene-therapy-utility 2026-07-22T13:10:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/all-five-longitude-health-member-systems-join-as-design-partners-for-cell-and-gene-therapy-utility 2026-07-22T13:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-vaccine-technology-and-r-d-sovereignty-africa-s-path-beyond-fill-and-finish 2026-07-22T13:10:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-vaccine-technology-and-r-d-sovereignty-africa-s-path-beyond-fill-and-finish 2026-07-22T13:10:34+00:00 hourly 0.9 https://trial.medpath.com/news/3p-innovation-delivers-custom-aseptic-reconstitutable-powder-filling-system-for-global-medtech-client 2026-07-22T13:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/3p-innovation-delivers-custom-aseptic-reconstitutable-powder-filling-system-for-global-medtech-client 2026-07-22T13:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-discontinues-phase-2-grpr-targeted-radioligand-lu-neob-in-breast-cancer-reaffirms-platform-commitment 2026-07-22T13:09:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-discontinues-phase-2-grpr-targeted-radioligand-lu-neob-in-breast-cancer-reaffirms-platform-commitment 2026-07-22T13:09:47+00:00 hourly 0.9 https://trial.medpath.com/news/hewlett-foundation-launches-100-million-initiative-targeting-ai-biotechnology-and-quantum-security 2026-07-22T13:09:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hewlett-foundation-launches-100-million-initiative-targeting-ai-biotechnology-and-quantum-security 2026-07-22T13:09:31+00:00 hourly 0.9 https://trial.medpath.com/news/flatiron-health-presents-three-real-world-evidence-studies-on-nsclc-treatment-patterns-at-wclc-2026 2026-07-22T13:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flatiron-health-presents-three-real-world-evidence-studies-on-nsclc-treatment-patterns-at-wclc-2026 2026-07-22T13:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/mira-launches-a-woman-s-maze-campaign-with-rumer-willis-to-address-gaps-in-women-s-hormonal-health-literacy 2026-07-22T12:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mira-launches-a-woman-s-maze-campaign-with-rumer-willis-to-address-gaps-in-women-s-hormonal-health-literacy 2026-07-22T12:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-ryaltris-nasal-spray-approval-to-children-aged-6-to-11-years-with-seasonal-allergic-rhinitis 2026-07-22T12:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-ryaltris-nasal-spray-approval-to-children-aged-6-to-11-years-with-seasonal-allergic-rhinitis 2026-07-22T12:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/ub-s-cheri-awards-over-600000-to-east-side-community-groups-and-researchers-to-tackle-social-determinants-of-health 2026-07-22T12:08:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ub-s-cheri-awards-over-600000-to-east-side-community-groups-and-researchers-to-tackle-social-determinants-of-health 2026-07-22T12:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-tops-inaugural-pipeline-to-patient-productivity-index-as-industry-r-d-efficiency-faces-mounting-pressure 2026-07-22T11:06:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-tops-inaugural-pipeline-to-patient-productivity-index-as-industry-r-d-efficiency-faces-mounting-pressure 2026-07-22T11:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/circulating-biomarkers-mediate-obesity-endometrial-cancer-link-with-distinct-pathways-in-pre-and-postmenopausal-women 2026-07-22T10:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circulating-biomarkers-mediate-obesity-endometrial-cancer-link-with-distinct-pathways-in-pre-and-postmenopausal-women 2026-07-22T10:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/non-tyrosine-kinase-inhibitors-market-to-reach-usd-18-7-billion-by-2036-driven-by-biomarker-linked-oncology-approvals 2026-07-22T10:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/non-tyrosine-kinase-inhibitors-market-to-reach-usd-18-7-billion-by-2036-driven-by-biomarker-linked-oncology-approvals 2026-07-22T10:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-medicine-hospital-of-hong-kong-launches-integrated-chinese-western-clinical-programmes-for-post-stroke-and-low-back-pain-care 2026-07-22T10:07:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-medicine-hospital-of-hong-kong-launches-integrated-chinese-western-clinical-programmes-for-post-stroke-and-low-back-pain-care 2026-07-22T10:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/jupiter-neurosciences-secures-exclusive-u-s-rights-to-pharmala-s-ala-002-in-deal-valued-at-up-to-100-million 2026-07-22T09:09:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jupiter-neurosciences-secures-exclusive-u-s-rights-to-pharmala-s-ala-002-in-deal-valued-at-up-to-100-million 2026-07-22T09:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/pd-1-backbone-contracts-across-u-s-clinical-trial-pipeline-as-keytruda-slide-extends 2026-07-22T09:08:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pd-1-backbone-contracts-across-u-s-clinical-trial-pipeline-as-keytruda-slide-extends 2026-07-22T09:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/mastel-surgical-receives-fda-510-k-clearance-for-steribest-sterilization-tray-system 2026-07-22T09:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mastel-surgical-receives-fda-510-k-clearance-for-steribest-sterilization-tray-system 2026-07-22T09:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/ai-designed-protein-and-needle-based-endoscope-overcome-dual-barriers-to-photothermal-cancer-therapy 2026-07-22T09:07:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-designed-protein-and-needle-based-endoscope-overcome-dual-barriers-to-photothermal-cancer-therapy 2026-07-22T09:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/tikva-allocell-closes-8m-series-a-to-advance-off-the-shelf-car-t-for-solid-tumors 2026-07-22T08:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tikva-allocell-closes-8m-series-a-to-advance-off-the-shelf-car-t-for-solid-tumors 2026-07-22T08:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/healx-doses-first-patient-in-phase-1-2-trial-of-hlx-4310-targeting-metastatic-recurrence-in-osteosarcoma 2026-07-22T08:08:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/healx-doses-first-patient-in-phase-1-2-trial-of-hlx-4310-targeting-metastatic-recurrence-in-osteosarcoma 2026-07-22T08:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/uk-humanitarian-worker-under-ebola-monitoring-in-london-following-potential-exposure-in-drc 2026-07-22T07:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-humanitarian-worker-under-ebola-monitoring-in-london-following-potential-exposure-in-drc 2026-07-22T07:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/sharp-rise-in-type-2-diabetes-among-young-women-in-england-sparks-concern 2026-07-22T05:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sharp-rise-in-type-2-diabetes-among-young-women-in-england-sparks-concern 2026-07-22T05:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/ctx001-gene-therapy-shows-early-tolerability-and-slowed-lesion-progression-in-geographic-atrophy 2026-07-22T05:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ctx001-gene-therapy-shows-early-tolerability-and-slowed-lesion-progression-in-geographic-atrophy 2026-07-22T05:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/tractor-mix-new-computational-method-uncovers-hidden-disease-linked-genes-in-diverse-populations 2026-07-22T03:07:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tractor-mix-new-computational-method-uncovers-hidden-disease-linked-genes-in-diverse-populations 2026-07-22T03:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/bill-ackman-commits-260-million-to-establish-brain-research-institute-in-manhattan-following-daughter-s-hemorrhage 2026-07-22T03:07:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bill-ackman-commits-260-million-to-establish-brain-research-institute-in-manhattan-following-daughter-s-hemorrhage 2026-07-22T03:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/trump-announces-phased-tariffs-on-generic-drugs-starting-2028-to-force-onshore-manufacturing 2026-07-22T02:14:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-announces-phased-tariffs-on-generic-drugs-starting-2028-to-force-onshore-manufacturing 2026-07-22T02:14:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-announces-nationwide-cetirizine-recall-after-cross-contamination-with-ranitidine-discovered 2026-07-22T01:07:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-announces-nationwide-cetirizine-recall-after-cross-contamination-with-ranitidine-discovered 2026-07-22T01:07:14+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-drug-parity-act-reintroduced-to-eliminate-out-of-pocket-cost-disparities-between-oral-and-iv-cancer-therapies 2026-07-22T01:07:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-drug-parity-act-reintroduced-to-eliminate-out-of-pocket-cost-disparities-between-oral-and-iv-cancer-therapies 2026-07-22T01:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/protein-partnership-specificity-explains-regional-brain-vulnerability-in-sca1-and-beyond 2026-07-22T00:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protein-partnership-specificity-explains-regional-brain-vulnerability-in-sca1-and-beyond 2026-07-22T00:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/maxcyte-licenses-multi-platform-cell-engineering-technology-to-genentech-for-cell-therapy-development 2026-07-22T00:07:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maxcyte-licenses-multi-platform-cell-engineering-technology-to-genentech-for-cell-therapy-development 2026-07-22T00:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/integrated-single-cell-and-spatial-transcriptomics-reveals-multicellular-programs-in-disease-pathogenesis 2026-07-21T23:08:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/integrated-single-cell-and-spatial-transcriptomics-reveals-multicellular-programs-in-disease-pathogenesis 2026-07-21T23:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/unsw-precision-care-clinic-expands-genomic-guided-cancer-care-to-over-200-australians-with-rare-tumours 2026-07-21T23:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unsw-precision-care-clinic-expands-genomic-guided-cancer-care-to-over-200-australians-with-rare-tumours 2026-07-21T23:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/harvard-business-school-names-2026-2027-blavatnik-fellows-marking-13th-cohort-of-life-science-entrepreneurs 2026-07-21T23:07:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harvard-business-school-names-2026-2027-blavatnik-fellows-marking-13th-cohort-of-life-science-entrepreneurs 2026-07-21T23:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/study-charts-raav-dose-costs-by-indication-and-identifies-cost-cutting-strategies 2026-07-21T21:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-charts-raav-dose-costs-by-indication-and-identifies-cost-cutting-strategies 2026-07-21T21:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-finds-new-dry-amd-therapies-do-not-increase-treatment-burden-for-wet-amd 2026-07-21T21:07:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-finds-new-dry-amd-therapies-do-not-increase-treatment-burden-for-wet-amd 2026-07-21T21:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/newly-discovered-braf-protein-conformation-offers-fresh-target-for-cancer-drug-development 2026-07-21T20:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/newly-discovered-braf-protein-conformation-offers-fresh-target-for-cancer-drug-development 2026-07-21T20:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-drugs-linked-to-17-reduction-in-long-term-sick-leave-economic-study-finds 2026-07-21T20:12:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-drugs-linked-to-17-reduction-in-long-term-sick-leave-economic-study-finds 2026-07-21T20:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-establishes-cross-center-framework-for-digital-measures-in-clinical-trials 2026-07-21T20:12:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-establishes-cross-center-framework-for-digital-measures-in-clinical-trials 2026-07-21T20:12:12+00:00 hourly 0.9 https://trial.medpath.com/news/thymulin-restrains-age-associated-myeloid-inflammation-and-enhances-cancer-immunotherapy-in-preclinical-models 2026-07-21T19:09:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thymulin-restrains-age-associated-myeloid-inflammation-and-enhances-cancer-immunotherapy-in-preclinical-models 2026-07-21T19:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/veeva-pushes-site-owned-esource-as-the-final-layer-in-clinical-trial-data-capture 2026-07-21T19:09:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veeva-pushes-site-owned-esource-as-the-final-layer-in-clinical-trial-data-capture 2026-07-21T19:09:47+00:00 hourly 0.9 https://trial.medpath.com/news/ensuring-supply-chain-reliability-and-regulatory-compliance-in-upstream-biopharmaceutical-manufacturing 2026-07-21T19:09:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensuring-supply-chain-reliability-and-regulatory-compliance-in-upstream-biopharmaceutical-manufacturing 2026-07-21T19:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/patientslikeme-and-science-37-forge-strategic-partnership-to-accelerate-clinical-trial-enrollment-and-expand-patient-access 2026-07-21T19:09:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patientslikeme-and-science-37-forge-strategic-partnership-to-accelerate-clinical-trial-enrollment-and-expand-patient-access 2026-07-21T19:09:17+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-achieves-95-complete-response-in-al-amyloidosis-trial-offering-new-hope-for-relapsed-patients 2026-07-21T18:10:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-achieves-95-complete-response-in-al-amyloidosis-trial-offering-new-hope-for-relapsed-patients 2026-07-21T18:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/intelligent-bio-solutions-completes-precision-testing-for-fda-510-k-submission-of-fingerprint-based-codeine-drug-screening-system 2026-07-21T18:10:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intelligent-bio-solutions-completes-precision-testing-for-fda-510-k-submission-of-fingerprint-based-codeine-drug-screening-system 2026-07-21T18:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/olorofim-shows-promise-for-severe-valley-fever-in-salvage-trial-offering-potential-curative-approach 2026-07-21T18:09:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olorofim-shows-promise-for-severe-valley-fever-in-salvage-trial-offering-potential-curative-approach 2026-07-21T18:09:06+00:00 hourly 0.9 https://trial.medpath.com/news/spain-unveils-comprehensive-drug-law-reform-with-dynamic-pricing-nurse-prescribing-and-strategic-medicine-provisions 2026-07-21T18:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spain-unveils-comprehensive-drug-law-reform-with-dynamic-pricing-nurse-prescribing-and-strategic-medicine-provisions 2026-07-21T18:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/medtech-pioneer-max-reinhardt-joins-exex-as-president-healthcare-to-drive-canopus-surgery-intelligence-platform-growth 2026-07-21T18:08:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtech-pioneer-max-reinhardt-joins-exex-as-president-healthcare-to-drive-canopus-surgery-intelligence-platform-growth 2026-07-21T18:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/novel-mrna-cancer-vaccine-prevents-melanoma-recurrence-in-high-risk-patients 2026-07-21T17:08:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-mrna-cancer-vaccine-prevents-melanoma-recurrence-in-high-risk-patients 2026-07-21T17:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-admits-using-keywords-to-terminate-billions-in-nih-and-federal-research-grants-at-university-of-california 2026-07-21T17:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-admits-using-keywords-to-terminate-billions-in-nih-and-federal-research-grants-at-university-of-california 2026-07-21T17:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/the-medicine-maker-power-list-2026-celebrates-60-leaders-driving-pharmaceutical-innovation-across-modalities 2026-07-21T17:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-medicine-maker-power-list-2026-celebrates-60-leaders-driving-pharmaceutical-innovation-across-modalities 2026-07-21T17:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/china-becomes-first-globally-to-approve-takeda-s-novel-narcolepsy-drug-tak-861 2026-07-21T17:06:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-becomes-first-globally-to-approve-takeda-s-novel-narcolepsy-drug-tak-861 2026-07-21T17:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/zeo-scientifix-to-expand-regenerative-medicine-operations-into-georgia-and-tennessee-after-new-state-laws-take-effect 2026-07-21T17:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zeo-scientifix-to-expand-regenerative-medicine-operations-into-georgia-and-tennessee-after-new-state-laws-take-effect 2026-07-21T17:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-s-pepfar-funding-cuts-cause-widespread-disruption-to-global-hiv-services-new-report-finds 2026-07-21T16:12:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-s-pepfar-funding-cuts-cause-widespread-disruption-to-global-hiv-services-new-report-finds 2026-07-21T16:12:05+00:00 hourly 0.9 https://trial.medpath.com/news/allogenetics-appoints-dr-jeroen-rovers-as-chief-medical-officer-to-advance-alg-115-toward-clinical-trials-in-lung-transplantation 2026-07-21T16:11:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allogenetics-appoints-dr-jeroen-rovers-as-chief-medical-officer-to-advance-alg-115-toward-clinical-trials-in-lung-transplantation 2026-07-21T16:11:46+00:00 hourly 0.9 https://trial.medpath.com/news/allergene-ai-therapeutics-to-unveil-first-in-class-in-vivo-mrna-lnp-car-t-platform-targeting-mast-cells-at-hanson-wade-summit 2026-07-21T16:10:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allergene-ai-therapeutics-to-unveil-first-in-class-in-vivo-mrna-lnp-car-t-platform-targeting-mast-cells-at-hanson-wade-summit 2026-07-21T16:10:53+00:00 hourly 0.9 https://trial.medpath.com/news/synergy-disc-reaches-100-u-s-cases-in-100-days-following-fda-approval-advancing-motion-preserving-cervical-disc-replacement 2026-07-21T16:10:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synergy-disc-reaches-100-u-s-cases-in-100-days-following-fda-approval-advancing-motion-preserving-cervical-disc-replacement 2026-07-21T16:10:33+00:00 hourly 0.9 https://trial.medpath.com/news/elephas-biosciences-expands-personalized-oncology-to-india-through-exclusive-partnership-with-neuberg-diagnostics 2026-07-21T16:10:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elephas-biosciences-expands-personalized-oncology-to-india-through-exclusive-partnership-with-neuberg-diagnostics 2026-07-21T16:10:12+00:00 hourly 0.9 https://trial.medpath.com/news/t-maximum-s-universal-car-t-mt027-to-debut-brain-metastasis-data-at-wclc-2026-as-intracranial-tumors-emerge-as-solid-tumor-car-t-s-second-battlefield 2026-07-21T16:09:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/t-maximum-s-universal-car-t-mt027-to-debut-brain-metastasis-data-at-wclc-2026-as-intracranial-tumors-emerge-as-solid-tumor-car-t-s-second-battlefield 2026-07-21T16:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/pharmather-partners-with-ketamist-inventor-to-pursue-fda-approval-for-needle-free-ketamine-platform-in-treatment-resistant-depression 2026-07-21T16:09:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmather-partners-with-ketamist-inventor-to-pursue-fda-approval-for-needle-free-ketamine-platform-in-treatment-resistant-depression 2026-07-21T16:09:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-emergency-use-authorization-to-seegene-s-allplex-multiplex-pcr-assay-for-simultaneous-detection-of-four-viral-pathogens 2026-07-21T16:09:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-emergency-use-authorization-to-seegene-s-allplex-multiplex-pcr-assay-for-simultaneous-detection-of-four-viral-pathogens 2026-07-21T16:09:11+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-sets-aside-refusal-of-array-biopharma-s-cancer-drug-combination-patent-orders-fresh-review 2026-07-21T16:08:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delhi-high-court-sets-aside-refusal-of-array-biopharma-s-cancer-drug-combination-patent-orders-fresh-review 2026-07-21T16:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/bioelectronics-doubles-facility-space-to-support-actipatch-dtc-launch-and-recoveryrx-demand 2026-07-21T16:08:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioelectronics-doubles-facility-space-to-support-actipatch-dtc-launch-and-recoveryrx-demand 2026-07-21T16:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/immorta-bio-and-collaborators-publish-blueprint-for-ai-driven-p4-precision-medicine-in-journal-of-translational-medicine 2026-07-21T16:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immorta-bio-and-collaborators-publish-blueprint-for-ai-driven-p4-precision-medicine-in-journal-of-translational-medicine 2026-07-21T16:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/medical-student-in-nepal-behind-international-research-factory-exposed-preprints-withdrawn 2026-07-21T15:07:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medical-student-in-nepal-behind-international-research-factory-exposed-preprints-withdrawn 2026-07-21T15:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/immitra-bio-raises-chf-2-4-million-to-advance-in-vivo-gene-editing-platform-for-inherited-anemia 2026-07-21T15:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immitra-bio-raises-chf-2-4-million-to-advance-in-vivo-gene-editing-platform-for-inherited-anemia 2026-07-21T15:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/who-marks-25-years-of-research4life-expanding-equitable-access-to-scientific-knowledge-across-120-countries 2026-07-21T15:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-marks-25-years-of-research4life-expanding-equitable-access-to-scientific-knowledge-across-120-countries 2026-07-21T15:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/icmr-licenses-three-indigenous-biomedical-technologies-to-emcure-and-biological-e-for-cancer-and-infectious-disease-control 2026-07-21T15:06:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icmr-licenses-three-indigenous-biomedical-technologies-to-emcure-and-biological-e-for-cancer-and-infectious-disease-control 2026-07-21T15:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/vesalio-s-envast-thrombectomy-system-nature-trial-selected-as-late-breaker-at-esc-congress-2026 2026-07-21T14:08:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vesalio-s-envast-thrombectomy-system-nature-trial-selected-as-late-breaker-at-esc-congress-2026 2026-07-21T14:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/dime-launches-initiative-to-translate-ai-governance-from-principle-to-practice-in-healthcare 2026-07-21T14:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dime-launches-initiative-to-translate-ai-governance-from-principle-to-practice-in-healthcare 2026-07-21T14:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/devonian-health-group-receives-health-canada-authorization-to-initiate-phase-ii-iii-pediatric-trial-of-thykamine-for-atopic-dermatitis 2026-07-21T14:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/devonian-health-group-receives-health-canada-authorization-to-initiate-phase-ii-iii-pediatric-trial-of-thykamine-for-atopic-dermatitis 2026-07-21T14:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/axiom-biosciences-plans-landmark-hong-kong-ipo-becoming-first-u-s-biotech-to-list-on-hkex 2026-07-21T13:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axiom-biosciences-plans-landmark-hong-kong-ipo-becoming-first-u-s-biotech-to-list-on-hkex 2026-07-21T13:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/nektar-launches-phase-3-zenith-ad-program-for-first-in-class-t-reg-biologic-rezpegaldesleukin-in-moderate-to-severe-atopic-dermatitis 2026-07-21T13:07:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nektar-launches-phase-3-zenith-ad-program-for-first-in-class-t-reg-biologic-rezpegaldesleukin-in-moderate-to-severe-atopic-dermatitis 2026-07-21T13:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-to-acquire-psychedelic-drugmaker-ataibeckley-for-2-8-billion 2026-07-21T13:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-to-acquire-psychedelic-drugmaker-ataibeckley-for-2-8-billion 2026-07-21T13:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/systematic-review-of-52053-patients-confirms-cancer-cachexia-erodes-function-and-quality-of-life-across-nearly-every-measure 2026-07-21T12:06:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/systematic-review-of-52053-patients-confirms-cancer-cachexia-erodes-function-and-quality-of-life-across-nearly-every-measure 2026-07-21T12:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-aso-gene-therapy-dramatically-reduces-seizures-and-restores-walking-in-children-with-scn2a-related-epilepsy 2026-07-21T10:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-aso-gene-therapy-dramatically-reduces-seizures-and-restores-walking-in-children-with-scn2a-related-epilepsy 2026-07-21T10:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/exempting-rare-disease-drugs-from-medicare-pricing-pilots-would-erase-most-retail-savings-harvard-analysis-finds 2026-07-21T10:07:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exempting-rare-disease-drugs-from-medicare-pricing-pilots-would-erase-most-retail-savings-harvard-analysis-finds 2026-07-21T10:07:47+00:00 hourly 0.9 https://trial.medpath.com/news/nanosystem-mediated-phototherapy-chemodynamic-therapy-synergistic-mechanisms-and-translational-barriers-in-precision-oncology 2026-07-21T08:07:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanosystem-mediated-phototherapy-chemodynamic-therapy-synergistic-mechanisms-and-translational-barriers-in-precision-oncology 2026-07-21T08:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/omeicos-omt-28-heads-directly-to-pivotal-phase-3-in-primary-mitochondrial-diseases-following-fda-endorsement 2026-07-21T08:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omeicos-omt-28-heads-directly-to-pivotal-phase-3-in-primary-mitochondrial-diseases-following-fda-endorsement 2026-07-21T08:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-spins-out-two-oncology-assets-into-kaveri-therapeutics-retains-82-2-controlling-stake 2026-07-21T07:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-spins-out-two-oncology-assets-into-kaveri-therapeutics-retains-82-2-controlling-stake 2026-07-21T07:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/innate-pharma-completes-enrollment-in-phase-1-dose-escalation-of-iph4502-a-novel-nectin-4-exatecan-adc-with-preliminary-data-expected-by-year-end 2026-07-21T07:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innate-pharma-completes-enrollment-in-phase-1-dose-escalation-of-iph4502-a-novel-nectin-4-exatecan-adc-with-preliminary-data-expected-by-year-end 2026-07-21T07:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/kansas-city-biohub-secures-34-million-federal-grant-to-advance-biomanufacturing-and-strengthen-domestic-drug-supply-chain 2026-07-21T07:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kansas-city-biohub-secures-34-million-federal-grant-to-advance-biomanufacturing-and-strengthen-domestic-drug-supply-chain 2026-07-21T07:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-enables-67-year-old-mantle-cell-lymphoma-survivor-to-paddle-2300-miles-after-four-years-cancer-free 2026-07-21T05:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-enables-67-year-old-mantle-cell-lymphoma-survivor-to-paddle-2300-miles-after-four-years-cancer-free 2026-07-21T05:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-and-ucsf-establish-master-collaboration-agreement-for-drug-discovery-research 2026-07-21T05:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-and-ucsf-establish-master-collaboration-agreement-for-drug-discovery-research 2026-07-21T05:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/dissolving-microneedles-show-dual-potential-to-enhance-drug-and-light-delivery-in-photodynamic-therapy-for-skin-cancer 2026-07-21T05:07:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dissolving-microneedles-show-dual-potential-to-enhance-drug-and-light-delivery-in-photodynamic-therapy-for-skin-cancer 2026-07-21T05:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/redwire-opens-space-based-pharmaceutical-research-and-manufacturing-facility-in-southern-indiana 2026-07-21T03:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redwire-opens-space-based-pharmaceutical-research-and-manufacturing-facility-in-southern-indiana 2026-07-21T03:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/aptar-beauty-launches-neodropper-autoload-next-generation-auto-loading-dropper-technology-debuts-with-dermalogica-s-futurecode-booster 2026-07-21T03:06:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptar-beauty-launches-neodropper-autoload-next-generation-auto-loading-dropper-technology-debuts-with-dermalogica-s-futurecode-booster 2026-07-21T03:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/colossal-biosciences-eyes-20b-30b-valuation-in-new-funding-round-doubling-prior-worth 2026-07-21T02:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/colossal-biosciences-eyes-20b-30b-valuation-in-new-funding-round-doubling-prior-worth 2026-07-21T02:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/verismo-therapeutics-expands-kir-car-solid-tumor-pipeline-with-novel-cldn6-binder-from-penn-collaboration 2026-07-21T01:06:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verismo-therapeutics-expands-kir-car-solid-tumor-pipeline-with-novel-cldn6-binder-from-penn-collaboration 2026-07-21T01:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/aft-pharmaceuticals-secures-fda-tentative-approval-for-scomara-in-facial-angiofibromas-us-launch-delayed-until-2029 2026-07-21T01:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aft-pharmaceuticals-secures-fda-tentative-approval-for-scomara-in-facial-angiofibromas-us-launch-delayed-until-2029 2026-07-21T01:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/gates-foundation-awards-540-million-10-year-grant-to-uw-s-ihme-to-strengthen-global-health-evidence 2026-07-21T00:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gates-foundation-awards-540-million-10-year-grant-to-uw-s-ihme-to-strengthen-global-health-evidence 2026-07-21T00:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/dignity-health-north-state-hospitals-earn-multiple-american-heart-association-awards-for-cardiovascular-and-stroke-care-excellence 2026-07-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dignity-health-north-state-hospitals-earn-multiple-american-heart-association-awards-for-cardiovascular-and-stroke-care-excellence 2026-07-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/investigator-initiated-trial-combining-doxorubicin-with-checkpoint-inhibitors-yields-durable-complete-response-in-metastatic-cardiac-sarcoma 2026-07-20T22:09:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/investigator-initiated-trial-combining-doxorubicin-with-checkpoint-inhibitors-yields-durable-complete-response-in-metastatic-cardiac-sarcoma 2026-07-20T22:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/virginia-s-advanced-pharmaceutical-manufacturing-tech-hub-secures-15-97-million-federal-investment-for-end-to-end-domestic-medicine-commercialization 2026-07-20T22:08:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virginia-s-advanced-pharmaceutical-manufacturing-tech-hub-secures-15-97-million-federal-investment-for-end-to-end-domestic-medicine-commercialization 2026-07-20T22:08:41+00:00 hourly 0.9 https://trial.medpath.com/news/pharmacy-benefit-trends-shaping-2026-glp-1-expansion-biosimilar-savings-and-shifting-anti-inflammatory-prescribing 2026-07-20T21:11:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmacy-benefit-trends-shaping-2026-glp-1-expansion-biosimilar-savings-and-shifting-anti-inflammatory-prescribing 2026-07-20T21:11:12+00:00 hourly 0.9 https://trial.medpath.com/news/brenus-pharma-secures-eur11m-series-a-extension-attracting-first-asia-pacific-investor-for-lead-immunotherapy-stc-1010 2026-07-20T21:10:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brenus-pharma-secures-eur11m-series-a-extension-attracting-first-asia-pacific-investor-for-lead-immunotherapy-stc-1010 2026-07-20T21:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/rising-antimicrobial-resistance-in-children-threatens-life-saving-antibiotics-globally-landmark-study-finds 2026-07-20T21:09:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rising-antimicrobial-resistance-in-children-threatens-life-saving-antibiotics-globally-landmark-study-finds 2026-07-20T21:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/seagen-s-antibody-drug-conjugate-pipeline-and-revenue-growth-anchor-investor-outlook-amid-oncology-competition 2026-07-20T19:11:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seagen-s-antibody-drug-conjugate-pipeline-and-revenue-growth-anchor-investor-outlook-amid-oncology-competition 2026-07-20T19:11:18+00:00 hourly 0.9 https://trial.medpath.com/news/conceivable-life-sciences-appoints-president-and-svp-of-commercial-operations-ahead-of-u-s-launch-of-world-s-first-automation-assisted-ivf-lab 2026-07-20T19:10:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/conceivable-life-sciences-appoints-president-and-svp-of-commercial-operations-ahead-of-u-s-launch-of-world-s-first-automation-assisted-ivf-lab 2026-07-20T19:10:54+00:00 hourly 0.9 https://trial.medpath.com/news/vogenx-raises-81-3m-in-nasdaq-ipo-to-advance-sglt1-inhibitor-mizagliflozin-in-metabolic-disorders 2026-07-20T19:10:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vogenx-raises-81-3m-in-nasdaq-ipo-to-advance-sglt1-inhibitor-mizagliflozin-in-metabolic-disorders 2026-07-20T19:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/epa-approves-crispr-based-hlb-resistant-citrus-rootstock-to-combat-citrus-greening 2026-07-20T19:09:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epa-approves-crispr-based-hlb-resistant-citrus-rootstock-to-combat-citrus-greening 2026-07-20T19:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/circulating-epigenetic-and-epitranscriptomic-biomarkers-identify-egfr-status-and-predict-tki-response-in-nsclc 2026-07-20T19:09:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circulating-epigenetic-and-epitranscriptomic-biomarkers-identify-egfr-status-and-predict-tki-response-in-nsclc 2026-07-20T19:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/vaxart-reports-favorable-safety-data-for-oral-covid-19-vaccine-eyes-2027-readout-for-5000-patient-cohort 2026-07-20T19:09:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaxart-reports-favorable-safety-data-for-oral-covid-19-vaccine-eyes-2027-readout-for-5000-patient-cohort 2026-07-20T19:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/rand-report-finds-stable-access-to-medical-care-for-most-injured-workers-but-flags-regional-gaps-in-california-s-workers-compensation-system 2026-07-20T18:09:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rand-report-finds-stable-access-to-medical-care-for-most-injured-workers-but-flags-regional-gaps-in-california-s-workers-compensation-system 2026-07-20T18:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/wellspan-health-hospitals-earn-u-s-news-best-hospitals-recognition-for-cardiovascular-rehabilitation-cancer-and-orthopedic-care 2026-07-20T18:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wellspan-health-hospitals-earn-u-s-news-best-hospitals-recognition-for-cardiovascular-rehabilitation-cancer-and-orthopedic-care 2026-07-20T18:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/uk-patents-court-rejects-msd-s-bid-for-wider-disclosure-in-halozyme-hyaluronidase-patent-dispute-over-keytruda-subcutaneous-formulation 2026-07-20T18:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-patents-court-rejects-msd-s-bid-for-wider-disclosure-in-halozyme-hyaluronidase-patent-dispute-over-keytruda-subcutaneous-formulation 2026-07-20T18:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/resmed-astral-100-150-ventilators-linked-to-serious-injuries-from-unexpected-therapy-interruption 2026-07-20T18:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/resmed-astral-100-150-ventilators-linked-to-serious-injuries-from-unexpected-therapy-interruption 2026-07-20T18:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/2026-cholesterol-guidelines-reveal-massive-treatment-gaps-1-in-3-americans-miss-ldl-goals-21-5-million-newly-eligible-for-statins 2026-07-20T16:11:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/2026-cholesterol-guidelines-reveal-massive-treatment-gaps-1-in-3-americans-miss-ldl-goals-21-5-million-newly-eligible-for-statins 2026-07-20T16:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-cancer-therapeutics-advance-from-molecular-design-to-clinical-trials 2026-07-20T16:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-cancer-therapeutics-advance-from-molecular-design-to-clinical-trials 2026-07-20T16:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/zhengye-biotechnology-stock-surges-68-amid-speculative-momentum-and-nasdaq-compliance-hopes 2026-07-20T16:10:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zhengye-biotechnology-stock-surges-68-amid-speculative-momentum-and-nasdaq-compliance-hopes 2026-07-20T16:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/psp-trial-platform-enrolls-first-participant-in-landmark-multi-drug-trial-for-progressive-supranuclear-palsy 2026-07-20T16:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psp-trial-platform-enrolls-first-participant-in-landmark-multi-drug-trial-for-progressive-supranuclear-palsy 2026-07-20T16:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/uc-san-diego-joins-innovative-genomics-institute-to-advance-next-generation-genome-editing-for-health-and-climate 2026-07-20T16:09:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-san-diego-joins-innovative-genomics-institute-to-advance-next-generation-genome-editing-for-health-and-climate 2026-07-20T16:09:17+00:00 hourly 0.9 https://trial.medpath.com/news/xenco-medical-unveils-xenvision-ai-powered-musculoskeletal-screening-platform-at-siggraph-2026 2026-07-20T16:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xenco-medical-unveils-xenvision-ai-powered-musculoskeletal-screening-platform-at-siggraph-2026 2026-07-20T16:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/ascp-and-pfizer-launch-quality-improvement-grants-to-advance-biomarker-testing-in-metastatic-colorectal-cancer 2026-07-20T16:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascp-and-pfizer-launch-quality-improvement-grants-to-advance-biomarker-testing-in-metastatic-colorectal-cancer 2026-07-20T16:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-ai-to-acquire-personalis-for-1-5-billion-adding-mrd-based-cancer-test-to-precision-oncology-portfolio 2026-07-20T16:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-ai-to-acquire-personalis-for-1-5-billion-adding-mrd-based-cancer-test-to-precision-oncology-portfolio 2026-07-20T16:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/fau-joins-3-8m-nih-funded-consortium-to-develop-novel-antimalarial-drugs-targeting-pfgarp 2026-07-20T15:17:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fau-joins-3-8m-nih-funded-consortium-to-develop-novel-antimalarial-drugs-targeting-pfgarp 2026-07-20T15:17:29+00:00 hourly 0.9 https://trial.medpath.com/news/dach-cleanroom-market-faces-drug-pricing-uncertainty-ai-impacts-and-consolidation-trends 2026-07-20T15:17:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dach-cleanroom-market-faces-drug-pricing-uncertainty-ai-impacts-and-consolidation-trends 2026-07-20T15:17:05+00:00 hourly 0.9 https://trial.medpath.com/news/abelzeta-s-c-car168-receives-ema-prime-designation-for-refractory-sle-and-lupus-nephritis 2026-07-20T15:15:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abelzeta-s-c-car168-receives-ema-prime-designation-for-refractory-sle-and-lupus-nephritis 2026-07-20T15:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in-alzheimer-s-disease-psychosis 2026-07-20T14:10:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in-alzheimer-s-disease-psychosis 2026-07-20T14:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/kinaset-therapeutics-doses-first-patient-in-phase-2b-panairama-trial-of-inhaled-pan-jak-inhibitor-frevecitinib-for-severe-asthma 2026-07-20T14:10:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kinaset-therapeutics-doses-first-patient-in-phase-2b-panairama-trial-of-inhaled-pan-jak-inhibitor-frevecitinib-for-severe-asthma 2026-07-20T14:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/nebraska-medicine-marks-a-decade-of-car-t-cell-therapy-innovation 2026-07-20T14:09:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nebraska-medicine-marks-a-decade-of-car-t-cell-therapy-innovation 2026-07-20T14:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/mentari-therapeutics-appoints-former-avadel-ceo-greg-divis-to-lead-migraine-pipeline-toward-regulatory-filings 2026-07-20T14:07:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mentari-therapeutics-appoints-former-avadel-ceo-greg-divis-to-lead-migraine-pipeline-toward-regulatory-filings 2026-07-20T14:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/vgll3-gene-dysregulation-identified-as-root-cause-of-preeclampsia-opening-door-to-new-diagnostics-and-treatments 2026-07-20T14:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vgll3-gene-dysregulation-identified-as-root-cause-of-preeclampsia-opening-door-to-new-diagnostics-and-treatments 2026-07-20T14:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/immuron-reports-four-consecutive-quarters-of-travelan-sales-growth-driven-by-australian-and-u-s-market-expansion 2026-07-20T13:07:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuron-reports-four-consecutive-quarters-of-travelan-sales-growth-driven-by-australian-and-u-s-market-expansion 2026-07-20T13:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-becomes-first-life-sciences-company-to-acquire-nvidia-s-vera-rubin-dgx-superpod-for-ai-driven-drug-discovery 2026-07-20T13:07:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-becomes-first-life-sciences-company-to-acquire-nvidia-s-vera-rubin-dgx-superpod-for-ai-driven-drug-discovery 2026-07-20T13:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/marengo-secures-esmo-2026-oral-presentation-for-phase-2-invikafusp-alfa-data-in-pd-1-resistant-solid-tumors-appoints-keytruda-development-leader-eric-rubin-to-scientific-advisory-board 2026-07-20T12:09:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marengo-secures-esmo-2026-oral-presentation-for-phase-2-invikafusp-alfa-data-in-pd-1-resistant-solid-tumors-appoints-keytruda-development-leader-eric-rubin-to-scientific-advisory-board 2026-07-20T12:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-phase-3-trial-shows-serplulimab-based-regimen-reduces-gastric-cancer-recurrence-risk-by-33-while-sparing-postoperative-chemotherapy 2026-07-20T12:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-phase-3-trial-shows-serplulimab-based-regimen-reduces-gastric-cancer-recurrence-risk-by-33-while-sparing-postoperative-chemotherapy 2026-07-20T12:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/ema-accepts-gsk-s-submission-for-single-dose-bexsero-booster-in-adolescents-and-young-adults 2026-07-20T12:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-accepts-gsk-s-submission-for-single-dose-bexsero-booster-in-adolescents-and-young-adults 2026-07-20T12:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/kolon-tissuegene-s-tg-c-fails-to-meet-co-primary-endpoints-in-first-u-s-phase-3-osteoarthritis-trial 2026-07-20T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kolon-tissuegene-s-tg-c-fails-to-meet-co-primary-endpoints-in-first-u-s-phase-3-osteoarthritis-trial 2026-07-20T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/india-approves-takeda-s-qdenga-its-first-dengue-vaccine-amid-11-fold-surge-in-cases 2026-07-20T11:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-approves-takeda-s-qdenga-its-first-dengue-vaccine-amid-11-fold-surge-in-cases 2026-07-20T11:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/aha-scientific-statement-up-to-400-mg-of-caffeine-daily-is-safe-for-most-adults-and-may-offer-cardiovascular-benefits 2026-07-20T10:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aha-scientific-statement-up-to-400-mg-of-caffeine-daily-is-safe-for-most-adults-and-may-offer-cardiovascular-benefits 2026-07-20T10:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/former-lifemd-employees-allege-patient-safety-compromised-in-pursuit-of-glp-1-prescription-volume 2026-07-20T10:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-lifemd-employees-allege-patient-safety-compromised-in-pursuit-of-glp-1-prescription-volume 2026-07-20T10:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-completes-randomization-in-landmark-deep-ocean-phase-iii-trial-of-bexicaserin-for-developmental-and-epileptic-encephalopathies 2026-07-20T09:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-completes-randomization-in-landmark-deep-ocean-phase-iii-trial-of-bexicaserin-for-developmental-and-epileptic-encephalopathies 2026-07-20T09:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/cytosurge-elects-biotech-veteran-luba-greenwood-to-board-as-it-builds-causal-data-foundation-for-ai-drug-discovery 2026-07-20T08:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytosurge-elects-biotech-veteran-luba-greenwood-to-board-as-it-builds-causal-data-foundation-for-ai-drug-discovery 2026-07-20T08:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/histone-lactylation-emerges-as-key-epigenetic-link-between-glycolysis-and-ferroptosis-in-neurological-diseases 2026-07-20T08:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/histone-lactylation-emerges-as-key-epigenetic-link-between-glycolysis-and-ferroptosis-in-neurological-diseases 2026-07-20T08:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/bile-acid-buildup-driven-by-gut-dysbiosis-fuels-breast-cancer-metastasis-uva-research-reveals 2026-07-20T08:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bile-acid-buildup-driven-by-gut-dysbiosis-fuels-breast-cancer-metastasis-uva-research-reveals 2026-07-20T08:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/beigene-raises-2026-revenue-guidance-as-brukinsa-sales-momentum-continues-cea-adc-data-slated-for-esmo-2026 2026-07-20T06:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beigene-raises-2026-revenue-guidance-as-brukinsa-sales-momentum-continues-cea-adc-data-slated-for-esmo-2026 2026-07-20T06:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/40-life-saving-medicines-remain-out-of-reach-in-pakistan-as-government-delays-price-approvals 2026-07-20T05:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/40-life-saving-medicines-remain-out-of-reach-in-pakistan-as-government-delays-price-approvals 2026-07-20T05:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/two-new-methods-break-down-forever-chemicals-in-water 2026-07-20T05:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-new-methods-break-down-forever-chemicals-in-water 2026-07-20T05:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/climate-variability-drives-nearly-one-million-infectious-disease-cases-in-coastal-sindh-over-four-years-study-finds 2026-07-20T05:07:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/climate-variability-drives-nearly-one-million-infectious-disease-cases-in-coastal-sindh-over-four-years-study-finds 2026-07-20T05:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/centenary-institute-s-2026-when-art-meets-science-image-prize-winners-reveal-the-hidden-beauty-of-medical-research 2026-07-20T05:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/centenary-institute-s-2026-when-art-meets-science-image-prize-winners-reveal-the-hidden-beauty-of-medical-research 2026-07-20T05:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/nppa-ramps-up-drug-price-enforcement-demand-notices-surge-four-fold-recoveries-jump-seven-fold-in-fy-2025-26 2026-07-20T04:07:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nppa-ramps-up-drug-price-enforcement-demand-notices-surge-four-fold-recoveries-jump-seven-fold-in-fy-2025-26 2026-07-20T04:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/antimicrobial-resistance-crisis-common-infections-becoming-harder-to-treat-as-drug-resistant-germs-spread-globally 2026-07-20T02:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antimicrobial-resistance-crisis-common-infections-becoming-harder-to-treat-as-drug-resistant-germs-spread-globally 2026-07-20T02:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/umbilical-cord-blood-biomarkers-uch-l1-and-gfap-reveal-fetal-neural-stress-in-maternal-sleep-disordered-breathing 2026-07-20T02:07:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/umbilical-cord-blood-biomarkers-uch-l1-and-gfap-reveal-fetal-neural-stress-in-maternal-sleep-disordered-breathing 2026-07-20T02:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-biologics-to-acquire-polypeptide-group-in-1-8-billion-deal-entering-the-booming-peptide-cdmo-market 2026-07-20T02:07:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-biologics-to-acquire-polypeptide-group-in-1-8-billion-deal-entering-the-booming-peptide-cdmo-market 2026-07-20T02:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/creative-life-science-showcases-pic-s-gmp-compliant-cell-therapy-manufacturing-platform-at-bio-asia-taiwan-2026 2026-07-20T01:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/creative-life-science-showcases-pic-s-gmp-compliant-cell-therapy-manufacturing-platform-at-bio-asia-taiwan-2026 2026-07-20T01:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/neuronata-r-retains-conditional-approval-in-south-korea-as-corestemchemon-eyes-u-s-expansion 2026-07-20T00:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuronata-r-retains-conditional-approval-in-south-korea-as-corestemchemon-eyes-u-s-expansion 2026-07-20T00:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/nsf-awards-15-million-to-iowa-state-led-ruralstamina-initiative-for-biomanufacturing-innovation-in-nebraska-and-iowa 2026-07-20T00:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nsf-awards-15-million-to-iowa-state-led-ruralstamina-initiative-for-biomanufacturing-innovation-in-nebraska-and-iowa 2026-07-20T00:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/silicon-chip-synthesizes-64-dna-sequences-in-water-advancing-enzymatic-dna-manufacturing 2026-07-20T00:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silicon-chip-synthesizes-64-dna-sequences-in-water-advancing-enzymatic-dna-manufacturing 2026-07-20T00:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/tissue-resident-memory-t-cells-explain-site-specific-relapse-in-atopic-dermatitis 2026-07-19T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tissue-resident-memory-t-cells-explain-site-specific-relapse-in-atopic-dermatitis 2026-07-19T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/mesoblast-advances-late-stage-pipeline-with-phase-3-progress-in-chronic-low-back-pain-and-bla-filing-for-heart-failure 2026-07-19T23:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mesoblast-advances-late-stage-pipeline-with-phase-3-progress-in-chronic-low-back-pain-and-bla-filing-for-heart-failure 2026-07-19T23:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/the-pink-salt-trick-experts-debunk-viral-tiktok-weight-loss-hack-warn-of-cardiovascular-risks 2026-07-19T22:08:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-pink-salt-trick-experts-debunk-viral-tiktok-weight-loss-hack-warn-of-cardiovascular-risks 2026-07-19T22:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/dbv-technologies-files-2026-half-year-report-and-schedules-second-quarter-financial-results-conference-call 2026-07-19T21:09:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dbv-technologies-files-2026-half-year-report-and-schedules-second-quarter-financial-results-conference-call 2026-07-19T21:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/japan-signals-strategic-shift-toward-open-innovation-and-cross-border-biotech-collaboration-at-bio-asia-taiwan-2026 2026-07-19T21:08:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-signals-strategic-shift-toward-open-innovation-and-cross-border-biotech-collaboration-at-bio-asia-taiwan-2026 2026-07-19T21:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/l7-bassist-jennifer-finch-dies-at-59-following-aggressive-brain-cancer-battle 2026-07-19T20:08:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/l7-bassist-jennifer-finch-dies-at-59-following-aggressive-brain-cancer-battle 2026-07-19T20:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/former-rhoc-star-jeana-keough-70-battling-tongue-cancer-after-squamous-cell-carcinoma-diagnosis 2026-07-19T20:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-rhoc-star-jeana-keough-70-battling-tongue-cancer-after-squamous-cell-carcinoma-diagnosis 2026-07-19T20:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/bacteria-convert-toxic-uranium-into-a-stable-compound-opening-new-paths-for-environmental-remediation 2026-07-19T18:06:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bacteria-convert-toxic-uranium-into-a-stable-compound-opening-new-paths-for-environmental-remediation 2026-07-19T18:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/tour-de-france-anti-doping-testers-wake-pogacar-and-vingegaard-in-early-hours-sparking-rider-backlash 2026-07-19T18:05:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tour-de-france-anti-doping-testers-wake-pogacar-and-vingegaard-in-early-hours-sparking-rider-backlash 2026-07-19T18:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/new-york-city-makes-controversial-cash-for-syringes-program-permanent-with-3-million-budget-allocation 2026-07-19T17:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-york-city-makes-controversial-cash-for-syringes-program-permanent-with-3-million-budget-allocation 2026-07-19T17:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/alcohol-related-liver-disease-diagnosis-spurs-early-drinking-cessation-but-37-relapse-within-90-days 2026-07-19T17:07:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alcohol-related-liver-disease-diagnosis-spurs-early-drinking-cessation-but-37-relapse-within-90-days 2026-07-19T17:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/tripura-sma-type-1-case-highlights-india-s-rare-disease-funding-gap-as-risdiplam-vials-supplied-zolgensma-awaits-dcgi-approval 2026-07-19T17:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tripura-sma-type-1-case-highlights-india-s-rare-disease-funding-gap-as-risdiplam-vials-supplied-zolgensma-awaits-dcgi-approval 2026-07-19T17:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/the-max-foundation-and-novartis-mark-25-year-partnership-built-on-equitable-global-access-to-care 2026-07-19T17:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-max-foundation-and-novartis-mark-25-year-partnership-built-on-equitable-global-access-to-care 2026-07-19T17:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/inovio-pharmaceuticals-faces-binary-outcome-as-fda-decision-on-ino-3107-looms-in-october-2026 2026-07-19T16:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inovio-pharmaceuticals-faces-binary-outcome-as-fda-decision-on-ino-3107-looms-in-october-2026 2026-07-19T16:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/caidya-and-simbec-orion-unite-to-form-a-differentiated-global-cro-spanning-first-in-human-to-registration 2026-07-19T16:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caidya-and-simbec-orion-unite-to-form-a-differentiated-global-cro-spanning-first-in-human-to-registration 2026-07-19T16:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/city-of-hope-ceo-robert-stone-honored-with-inaugural-lifetime-achievement-award-outlines-vision-for-ai-driven-cancer-care-and-national-expansion 2026-07-19T15:07:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/city-of-hope-ceo-robert-stone-honored-with-inaugural-lifetime-achievement-award-outlines-vision-for-ai-driven-cancer-care-and-national-expansion 2026-07-19T15:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/usfda-classifies-cipla-s-invagen-new-york-unit-3-inspection-as-voluntary-action-indicated 2026-07-19T14:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usfda-classifies-cipla-s-invagen-new-york-unit-3-inspection-as-voluntary-action-indicated 2026-07-19T14:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/dubai-launches-uae-s-first-national-digital-platform-for-addiction-recovery-masar-wellness 2026-07-19T14:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dubai-launches-uae-s-first-national-digital-platform-for-addiction-recovery-masar-wellness 2026-07-19T14:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/south-korea-remains-among-five-oecd-nations-blocking-abortion-pill-access-as-101-countries-adopt-who-essential-medication 2026-07-19T14:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-korea-remains-among-five-oecd-nations-blocking-abortion-pill-access-as-101-countries-adopt-who-essential-medication 2026-07-19T14:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/merck-group-announces-strategic-restructuring-of-israeli-operations-cutting-dozens-of-jobs-while-pivoting-toward-ai-driven-drug-development 2026-07-19T12:06:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-group-announces-strategic-restructuring-of-israeli-operations-cutting-dozens-of-jobs-while-pivoting-toward-ai-driven-drug-development 2026-07-19T12:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/gumitide-and-burntide-launch-2026-weight-loss-gummies-apple-cider-vinegar-and-bhb-formulas-enter-the-supplement-market 2026-07-19T11:06:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gumitide-and-burntide-launch-2026-weight-loss-gummies-apple-cider-vinegar-and-bhb-formulas-enter-the-supplement-market 2026-07-19T11:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/ozempic-culture-how-glp-1-drugs-are-reshaping-beauty-standards-and-the-cultural-imagination 2026-07-19T09:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ozempic-culture-how-glp-1-drugs-are-reshaping-beauty-standards-and-the-cultural-imagination 2026-07-19T09:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/frankfurt-airport-employee-dies-of-malaria-in-rare-airport-malaria-outbreak 2026-07-19T08:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/frankfurt-airport-employee-dies-of-malaria-in-rare-airport-malaria-outbreak 2026-07-19T08:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/south-korea-revisits-mifepristone-approval-amid-seven-year-abortion-law-vacuum 2026-07-19T08:07:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-korea-revisits-mifepristone-approval-amid-seven-year-abortion-law-vacuum 2026-07-19T08:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-trading-signals-highlight-divergent-sentiment-in-biotech-etfs-fbt-and-bbc 2026-07-19T04:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-driven-trading-signals-highlight-divergent-sentiment-in-biotech-etfs-fbt-and-bbc 2026-07-19T04:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/robert-koch-institute-to-host-3rd-symposium-on-artificial-intelligence-in-public-health-research-in-berlin 2026-07-19T01:08:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/robert-koch-institute-to-host-3rd-symposium-on-artificial-intelligence-in-public-health-research-in-berlin 2026-07-19T01:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/alexandria-real-estate-posts-73-7m-q2-loss-as-life-sciences-real-estate-slump-deepens 2026-07-19T00:09:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alexandria-real-estate-posts-73-7m-q2-loss-as-life-sciences-real-estate-slump-deepens 2026-07-19T00:09:29+00:00 hourly 0.9 https://trial.medpath.com/news/colestzen-launches-cholesterol-support-supplement-in-us-uk-canada-and-australia-markets 2026-07-19T00:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/colestzen-launches-cholesterol-support-supplement-in-us-uk-canada-and-australia-markets 2026-07-19T00:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/validating-tracheal-aspirates-for-microbiome-profiling-in-icu-pneumonia-patients 2026-07-18T23:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/validating-tracheal-aspirates-for-microbiome-profiling-in-icu-pneumonia-patients 2026-07-18T23:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/type-1-diabetes-may-cause-false-positive-celiac-blood-tests-complicating-screening-in-children 2026-07-18T23:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/type-1-diabetes-may-cause-false-positive-celiac-blood-tests-complicating-screening-in-children 2026-07-18T23:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/natco-pharma-secures-usfda-tentative-approval-for-generic-olaparib-tablets-partnering-with-alembic-for-u-s-distribution 2026-07-18T19:10:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natco-pharma-secures-usfda-tentative-approval-for-generic-olaparib-tablets-partnering-with-alembic-for-u-s-distribution 2026-07-18T19:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/brachytherapy-precision-radiation-oncology-s-high-value-underappreciated-modality-gains-renewed-recognition 2026-07-18T19:09:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brachytherapy-precision-radiation-oncology-s-high-value-underappreciated-modality-gains-renewed-recognition 2026-07-18T19:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/asrs-2026-durable-retina-therapies-take-center-stage-as-gene-therapy-implant-and-oral-data-mature 2026-07-18T19:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asrs-2026-durable-retina-therapies-take-center-stage-as-gene-therapy-implant-and-oral-data-mature 2026-07-18T19:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/from-fashion-week-to-cancer-free-a-model-s-journey-with-triple-negative-breast-cancer-highlights-barriers-to-timely-care 2026-07-18T19:09:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/from-fashion-week-to-cancer-free-a-model-s-journey-with-triple-negative-breast-cancer-highlights-barriers-to-timely-care 2026-07-18T19:09:17+00:00 hourly 0.9 https://trial.medpath.com/news/prenatal-estrogen-in-early-pregnancy-linked-to-male-newborn-brain-size-twin-studies-show 2026-07-18T18:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prenatal-estrogen-in-early-pregnancy-linked-to-male-newborn-brain-size-twin-studies-show 2026-07-18T18:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-to-launch-cheaper-ozempic-copy-in-south-africa-through-acino-partnership 2026-07-18T18:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-to-launch-cheaper-ozempic-copy-in-south-africa-through-acino-partnership 2026-07-18T18:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/dbv-technologies-renews-150-million-at-the-market-offering-program-to-fund-viaskin-r-peanut-development-and-pre-commercial-activities 2026-07-18T18:06:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dbv-technologies-renews-150-million-at-the-market-offering-program-to-fund-viaskin-r-peanut-development-and-pre-commercial-activities 2026-07-18T18:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-atezolizumab-plus-chemotherapy-is-feasible-and-safe-first-line-therapy-for-extensive-stage-small-cell-lung-cancer 2026-07-18T17:09:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-confirms-atezolizumab-plus-chemotherapy-is-feasible-and-safe-first-line-therapy-for-extensive-stage-small-cell-lung-cancer 2026-07-18T17:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/quebec-launches-first-ever-genomic-medicine-policy-to-advance-precision-medicine-across-the-province 2026-07-18T17:08:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quebec-launches-first-ever-genomic-medicine-policy-to-advance-precision-medicine-across-the-province 2026-07-18T17:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/custom-synthia-search-configuration-cuts-synthesis-route-planning-to-hours-case-study-shows 2026-07-18T17:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/custom-synthia-search-configuration-cuts-synthesis-route-planning-to-hours-case-study-shows 2026-07-18T17:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/somatic-mutations-cap-human-lifespan-at-146-194-years-even-if-all-other-aging-hallmarks-are-cured-study-finds 2026-07-18T17:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/somatic-mutations-cap-human-lifespan-at-146-194-years-even-if-all-other-aging-hallmarks-are-cured-study-finds 2026-07-18T17:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-researchers-discover-novel-hla-allele-hla-dqb1-03-03-38-with-clinical-promise 2026-07-18T17:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-researchers-discover-novel-hla-allele-hla-dqb1-03-03-38-with-clinical-promise 2026-07-18T17:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/latigo-biotherapeutics-files-for-ipo-as-non-opioid-pain-drug-ltg-001-advances-to-late-stage-testing 2026-07-18T17:07:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/latigo-biotherapeutics-files-for-ipo-as-non-opioid-pain-drug-ltg-001-advances-to-late-stage-testing 2026-07-18T17:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-pharma-india-ceases-manufacturing-operations-in-strategic-pivot-to-office-based-model 2026-07-18T16:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-pharma-india-ceases-manufacturing-operations-in-strategic-pivot-to-office-based-model 2026-07-18T16:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/cathie-wood-doubles-down-on-ionis-pharmaceuticals-amid-eplontersen-setback-and-tryngolza-market-expansion 2026-07-18T16:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cathie-wood-doubles-down-on-ionis-pharmaceuticals-amid-eplontersen-setback-and-tryngolza-market-expansion 2026-07-18T16:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/neighborhood-disadvantage-accelerates-cardiovascular-decline-in-midlife-women-two-decade-study-finds 2026-07-18T16:07:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neighborhood-disadvantage-accelerates-cardiovascular-decline-in-midlife-women-two-decade-study-finds 2026-07-18T16:07:14+00:00 hourly 0.9 https://trial.medpath.com/news/high-social-media-use-linked-to-youth-anxiety-and-suicidal-ideation-new-longitudinal-study-finds 2026-07-18T14:08:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-social-media-use-linked-to-youth-anxiety-and-suicidal-ideation-new-longitudinal-study-finds 2026-07-18T14:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/faulty-hospital-drug-tests-disproportionately-flag-black-newborns-to-law-enforcement-analysis-finds 2026-07-18T13:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faulty-hospital-drug-tests-disproportionately-flag-black-newborns-to-law-enforcement-analysis-finds 2026-07-18T13:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/v-foundation-awards-1-8-million-to-chop-researchers-for-car-t-cell-therapy-and-liquid-biopsy-advances-in-pediatric-cancer 2026-07-18T13:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/v-foundation-awards-1-8-million-to-chop-researchers-for-car-t-cell-therapy-and-liquid-biopsy-advances-in-pediatric-cancer 2026-07-18T13:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/chemotherapy-induced-cognitive-impairment-a-first-person-account-of-chemo-brain-and-its-impact-on-professional-function 2026-07-18T13:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chemotherapy-induced-cognitive-impairment-a-first-person-account-of-chemo-brain-and-its-impact-on-professional-function 2026-07-18T13:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/hcg-aastha-cancer-centre-achieves-first-car-t-cell-therapy-milestone-for-refractory-lymphoma-in-gujarat 2026-07-18T13:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hcg-aastha-cancer-centre-achieves-first-car-t-cell-therapy-milestone-for-refractory-lymphoma-in-gujarat 2026-07-18T13:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/harmony-biosciences-reports-phase-1-data-for-orexin-2-agonist-bp-205-reinforcing-best-in-class-potential 2026-07-18T13:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harmony-biosciences-reports-phase-1-data-for-orexin-2-agonist-bp-205-reinforcing-best-in-class-potential 2026-07-18T13:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/exact-sciences-seeks-director-of-medical-development-to-lead-mrd-breast-cancer-portfolio-strategy 2026-07-18T13:07:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exact-sciences-seeks-director-of-medical-development-to-lead-mrd-breast-cancer-portfolio-strategy 2026-07-18T13:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/parotid-gland-cancer-in-young-adults-a-case-study-of-diagnosis-treatment-and-recovery 2026-07-18T11:06:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parotid-gland-cancer-in-young-adults-a-case-study-of-diagnosis-treatment-and-recovery 2026-07-18T11:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/endothelial-klf4-loss-identified-as-key-driver-of-blood-brain-barrier-breakdown-and-age-related-cognitive-decline 2026-07-18T09:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/endothelial-klf4-loss-identified-as-key-driver-of-blood-brain-barrier-breakdown-and-age-related-cognitive-decline 2026-07-18T09:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-weight-loss-drugs-enter-clinical-trials-for-obese-cats-as-pet-care-shifts-toward-medicalization 2026-07-18T08:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-weight-loss-drugs-enter-clinical-trials-for-obese-cats-as-pet-care-shifts-toward-medicalization 2026-07-18T08:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/sun-fanglin-pioneering-chinese-cancer-researcher-who-uncovered-pathways-to-reverse-drug-resistance-dies-at-58 2026-07-18T08:07:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-fanglin-pioneering-chinese-cancer-researcher-who-uncovered-pathways-to-reverse-drug-resistance-dies-at-58 2026-07-18T08:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/rara-targeting-protac-delivered-by-plant-nanoparticles-shows-potent-activity-in-colorectal-cancer 2026-07-18T00:08:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rara-targeting-protac-delivered-by-plant-nanoparticles-shows-potent-activity-in-colorectal-cancer 2026-07-18T00:08:41+00:00 hourly 0.9 https://trial.medpath.com/news/patient-derived-pancreatic-organoids-uncover-cftr-dysfunction-as-therapeutic-target-in-chronic-pancreatitis 2026-07-18T00:08:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-derived-pancreatic-organoids-uncover-cftr-dysfunction-as-therapeutic-target-in-chronic-pancreatitis 2026-07-18T00:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/topology-based-biomarkers-outperform-traditional-methods-in-predicting-breast-cancer-survival 2026-07-17T23:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/topology-based-biomarkers-outperform-traditional-methods-in-predicting-breast-cancer-survival 2026-07-17T23:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/emestedastat-shows-late-emerging-antidepressant-signal-in-difficult-to-treat-mdd-despite-missing-cognitive-endpoint 2026-07-17T22:09:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emestedastat-shows-late-emerging-antidepressant-signal-in-difficult-to-treat-mdd-despite-missing-cognitive-endpoint 2026-07-17T22:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/icgeb-opens-september-2026-fellowship-call-with-new-two-stage-application-process 2026-07-17T22:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icgeb-opens-september-2026-fellowship-call-with-new-two-stage-application-process 2026-07-17T22:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/nuvox-therapeutics-files-for-20-million-ipo-to-advance-hypoxia-targeting-nano2-platform 2026-07-17T21:09:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuvox-therapeutics-files-for-20-million-ipo-to-advance-hypoxia-targeting-nano2-platform 2026-07-17T21:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/linking-clinical-trial-data-with-real-world-data-methodologies-and-recommendations-for-enhanced-evidence-generation 2026-07-17T20:09:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/linking-clinical-trial-data-with-real-world-data-methodologies-and-recommendations-for-enhanced-evidence-generation 2026-07-17T20:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/belarusian-scientists-leverage-ai-for-drug-repurposing-target-identification-and-de-novo-molecule-design 2026-07-17T19:09:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belarusian-scientists-leverage-ai-for-drug-repurposing-target-identification-and-de-novo-molecule-design 2026-07-17T19:09:48+00:00 hourly 0.9 https://trial.medpath.com/news/inflammasome-therapeutics-k8-slows-geographic-atrophy-lesion-growth-by-54-and-shows-visual-acuity-benefit-in-phase-2-trial 2026-07-17T19:08:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inflammasome-therapeutics-k8-slows-geographic-atrophy-lesion-growth-by-54-and-shows-visual-acuity-benefit-in-phase-2-trial 2026-07-17T19:08:49+00:00 hourly 0.9 https://trial.medpath.com/news/wildfire-smoke-a-systemic-threat-to-human-health-from-acute-inflammation-to-cancer-and-dementia 2026-07-17T18:09:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wildfire-smoke-a-systemic-threat-to-human-health-from-acute-inflammation-to-cancer-and-dementia 2026-07-17T18:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-human-spinal-interneurons-restore-breathing-function-in-injured-rats-paving-way-for-regenerative-therapies 2026-07-17T18:08:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-human-spinal-interneurons-restore-breathing-function-in-injured-rats-paving-way-for-regenerative-therapies 2026-07-17T18:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/md-anderson-receives-1-82-million-nci-grant-to-investigate-bhlhe40-transcription-factor-as-novel-target-for-improving-immunotherapy-response 2026-07-17T17:09:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/md-anderson-receives-1-82-million-nci-grant-to-investigate-bhlhe40-transcription-factor-as-novel-target-for-improving-immunotherapy-response 2026-07-17T17:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/glioblastoma-patient-sells-home-to-access-experimental-treatments-unavailable-on-the-nhs-highlighting-urgent-need-for-research-investment 2026-07-17T17:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glioblastoma-patient-sells-home-to-access-experimental-treatments-unavailable-on-the-nhs-highlighting-urgent-need-for-research-investment 2026-07-17T17:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/russian-scientists-develop-hybrid-molecules-that-evade-cancer-drug-resistance 2026-07-17T17:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/russian-scientists-develop-hybrid-molecules-that-evade-cancer-drug-resistance 2026-07-17T17:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/blossomhill-therapeutics-files-for-100m-nasdaq-ipo-to-advance-macrocyclic-cancer-pipeline 2026-07-17T17:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blossomhill-therapeutics-files-for-100m-nasdaq-ipo-to-advance-macrocyclic-cancer-pipeline 2026-07-17T17:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/elastography-and-blood-biomarkers-improve-early-detection-of-sinusoidal-obstruction-syndrome-after-stem-cell-transplant 2026-07-17T17:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elastography-and-blood-biomarkers-improve-early-detection-of-sinusoidal-obstruction-syndrome-after-stem-cell-transplant 2026-07-17T17:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/bemotrizinol-bemt-cleared-by-fda-a-new-photostable-chemical-sunscreen-filter-reaches-the-u-s-market 2026-07-17T16:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bemotrizinol-bemt-cleared-by-fda-a-new-photostable-chemical-sunscreen-filter-reaches-the-u-s-market 2026-07-17T16:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/jcvi-recommends-csl-seqirus-aujemflu-for-2027-28-uk-flu-season-moderna-s-mrna-vaccine-deferred 2026-07-17T16:10:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jcvi-recommends-csl-seqirus-aujemflu-for-2027-28-uk-flu-season-moderna-s-mrna-vaccine-deferred 2026-07-17T16:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/ai-and-biosecurity-risks-outpace-federal-regulatory-response-crs-report-warns 2026-07-17T16:10:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-and-biosecurity-risks-outpace-federal-regulatory-response-crs-report-warns 2026-07-17T16:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-halts-camlipixant-development-for-refractory-chronic-cough-after-dual-phase-iii-trial-failure 2026-07-17T16:10:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-halts-camlipixant-development-for-refractory-chronic-cough-after-dual-phase-iii-trial-failure 2026-07-17T16:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/aqemia-and-sanofi-expand-ai-drug-discovery-collaboration-with-new-target-nomination 2026-07-17T16:09:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aqemia-and-sanofi-expand-ai-drug-discovery-collaboration-with-new-target-nomination 2026-07-17T16:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/nevada-ag-joins-400-million-settlement-with-sandoz-over-generic-drug-price-fixing-conspiracy 2026-07-17T16:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nevada-ag-joins-400-million-settlement-with-sandoz-over-generic-drug-price-fixing-conspiracy 2026-07-17T16:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/kourtney-kardashian-s-lemme-launches-skin-firming-hydrating-gummy-rings-with-ceramosides 2026-07-17T16:09:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kourtney-kardashian-s-lemme-launches-skin-firming-hydrating-gummy-rings-with-ceramosides 2026-07-17T16:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/enzyme-powered-dna-encoded-libraries-a-gentler-path-to-small-molecule-drug-discovery 2026-07-17T16:07:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enzyme-powered-dna-encoded-libraries-a-gentler-path-to-small-molecule-drug-discovery 2026-07-17T16:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/combination-therapies-emerge-as-a-path-to-disease-modification-in-parkinson-s-disease 2026-07-17T15:08:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combination-therapies-emerge-as-a-path-to-disease-modification-in-parkinson-s-disease 2026-07-17T15:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/finger-prick-glucose-ketone-index-test-proposed-as-practical-tool-to-monitor-mitochondrial-and-metabolic-health 2026-07-17T15:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/finger-prick-glucose-ketone-index-test-proposed-as-practical-tool-to-monitor-mitochondrial-and-metabolic-health 2026-07-17T15:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/iveena-delivery-systems-announces-successful-phase-1-results-for-ivmed-85-a-first-in-class-lysyl-oxidase-activator-for-pediatric-myopia 2026-07-17T15:08:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iveena-delivery-systems-announces-successful-phase-1-results-for-ivmed-85-a-first-in-class-lysyl-oxidase-activator-for-pediatric-myopia 2026-07-17T15:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/thalassax-doses-first-u-s-patient-in-phase-i-trial-of-brain-penetrant-aurora-b-kinase-inhibitor-cs231295 2026-07-17T15:08:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thalassax-doses-first-u-s-patient-in-phase-i-trial-of-brain-penetrant-aurora-b-kinase-inhibitor-cs231295 2026-07-17T15:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-stage-partnering-and-royalty-rate-trends-in-biopharma-new-reports-analyze-over-3400-deals-from-2015-2026 2026-07-17T15:07:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-stage-partnering-and-royalty-rate-trends-in-biopharma-new-reports-analyze-over-3400-deals-from-2015-2026 2026-07-17T15:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/aptar-pharma-launches-integrated-system-level-framework-to-support-injectable-drug-development 2026-07-17T15:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptar-pharma-launches-integrated-system-level-framework-to-support-injectable-drug-development 2026-07-17T15:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/dna-script-expands-on-demand-enzymatic-dna-synthesis-to-india-through-imperial-life-sciences-partnership 2026-07-17T15:07:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dna-script-expands-on-demand-enzymatic-dna-synthesis-to-india-through-imperial-life-sciences-partnership 2026-07-17T15:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/g-h-to-showcase-integrated-diagnostic-device-development-and-manufacturing-capabilities-at-adlm-2026 2026-07-17T13:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/g-h-to-showcase-integrated-diagnostic-device-development-and-manufacturing-capabilities-at-adlm-2026 2026-07-17T13:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/antisense-oligonucleotides-rewriting-the-future-of-rare-inherited-genetic-diseases 2026-07-17T13:14:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antisense-oligonucleotides-rewriting-the-future-of-rare-inherited-genetic-diseases 2026-07-17T13:14:44+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-launches-trupath-genome-a-395-whole-genome-workflow-targeting-rare-genetic-disease 2026-07-17T13:14:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illumina-launches-trupath-genome-a-395-whole-genome-workflow-targeting-rare-genetic-disease 2026-07-17T13:14:43+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-secures-fda-approval-for-additional-generic-iohexol-injection-vial-presentations-expanding-contrast-media-portfolio 2026-07-17T13:14:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amneal-secures-fda-approval-for-additional-generic-iohexol-injection-vial-presentations-expanding-contrast-media-portfolio 2026-07-17T13:14:29+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-nhs-approval-of-dabrafenib-and-brentuximab-vedotin-combination-offers-new-hope-for-patients-with-rare-blood-cancers 2026-07-17T12:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-nhs-approval-of-dabrafenib-and-brentuximab-vedotin-combination-offers-new-hope-for-patients-with-rare-blood-cancers 2026-07-17T12:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/new-review-calls-for-prioritizing-maternal-mental-health-and-ssri-treatment-during-pregnancy 2026-07-17T11:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-review-calls-for-prioritizing-maternal-mental-health-and-ssri-treatment-during-pregnancy 2026-07-17T11:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-halts-camlipixant-development-for-refractory-chronic-cough-after-mixed-phase-iii-results 2026-07-17T11:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-halts-camlipixant-development-for-refractory-chronic-cough-after-mixed-phase-iii-results 2026-07-17T11:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/human-cells-are-rewriting-the-rules-of-drug-development-ipscs-organoids-and-ai-converge-to-challenge-animal-models 2026-07-17T10:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/human-cells-are-rewriting-the-rules-of-drug-development-ipscs-organoids-and-ai-converge-to-challenge-animal-models 2026-07-17T10:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/the-next-era-of-aesthetic-medicine-from-treatment-stacking-to-regenerative-science 2026-07-17T09:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-next-era-of-aesthetic-medicine-from-treatment-stacking-to-regenerative-science 2026-07-17T09:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-mrna-cancer-vaccine-clears-phase-3-moderna-and-merck-s-intismeran-autogene-succeeds-in-melanoma-trial 2026-07-17T09:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-mrna-cancer-vaccine-clears-phase-3-moderna-and-merck-s-intismeran-autogene-succeeds-in-melanoma-trial 2026-07-17T09:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/nurse-calls-for-mandatory-drug-safety-training-in-guernsey-to-address-gaps-in-adverse-drug-reaction-reporting 2026-07-17T08:07:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nurse-calls-for-mandatory-drug-safety-training-in-guernsey-to-address-gaps-in-adverse-drug-reaction-reporting 2026-07-17T08:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/natera-s-signatera-becomes-first-approved-mrd-test-for-colorectal-cancer-in-japan 2026-07-17T06:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natera-s-signatera-becomes-first-approved-mrd-test-for-colorectal-cancer-in-japan 2026-07-17T06:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/three-strategies-to-reduce-data-friction-and-build-leaner-clinical-data-management-operations 2026-07-17T06:07:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-strategies-to-reduce-data-friction-and-build-leaner-clinical-data-management-operations 2026-07-17T06:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/dna-nanoplatform-delivers-dual-agent-therapy-to-combat-periodontitis-in-preclinical-study 2026-07-17T05:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dna-nanoplatform-delivers-dual-agent-therapy-to-combat-periodontitis-in-preclinical-study 2026-07-17T05:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-research-agency-terminates-dozens-of-health-services-grants-halting-patient-care-studies-nationwide 2026-07-17T02:23:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hhs-research-agency-terminates-dozens-of-health-services-grants-halting-patient-care-studies-nationwide 2026-07-17T02:23:32+00:00 hourly 0.9 https://trial.medpath.com/news/lig1-loss-exposes-therapeutic-vulnerability-in-chemotherapy-resistant-triple-negative-breast-cancer 2026-07-17T02:23:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lig1-loss-exposes-therapeutic-vulnerability-in-chemotherapy-resistant-triple-negative-breast-cancer 2026-07-17T02:23:26+00:00 hourly 0.9 https://trial.medpath.com/news/phgdh-driven-epigenetic-silencing-creates-immune-scarce-sanctuary-for-metastatic-seeds 2026-07-17T02:22:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phgdh-driven-epigenetic-silencing-creates-immune-scarce-sanctuary-for-metastatic-seeds 2026-07-17T02:22:29+00:00 hourly 0.9 https://trial.medpath.com/news/terminally-ill-glioblastoma-patients-turn-to-unproven-treatments-abroad-amid-calls-for-more-uk-brain-cancer-research 2026-07-17T02:21:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/terminally-ill-glioblastoma-patients-turn-to-unproven-treatments-abroad-amid-calls-for-more-uk-brain-cancer-research 2026-07-17T02:21:32+00:00 hourly 0.9 https://trial.medpath.com/news/house-bill-proposes-dedicated-biotechnology-official-at-the-state-department 2026-07-17T01:05:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/house-bill-proposes-dedicated-biotechnology-official-at-the-state-department 2026-07-17T01:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/the-test-of-time-why-breakthrough-drugs-so-often-disappoint 2026-07-17T00:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-test-of-time-why-breakthrough-drugs-so-often-disappoint 2026-07-17T00:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/senate-pushes-for-audit-of-tricare-pharmacy-program-amid-conflict-of-interest-concerns-over-express-scripts-dual-role 2026-07-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senate-pushes-for-audit-of-tricare-pharmacy-program-amid-conflict-of-interest-concerns-over-express-scripts-dual-role 2026-07-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/porcine-rotavirus-vaccines-face-a-cross-protection-gap-as-reassortant-strains-emerge 2026-07-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/porcine-rotavirus-vaccines-face-a-cross-protection-gap-as-reassortant-strains-emerge 2026-07-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/rare-gist-diagnosis-at-31-highlights-critical-need-for-early-detection-and-awareness-of-gastrointestinal-stromal-tumours 2026-07-16T23:08:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rare-gist-diagnosis-at-31-highlights-critical-need-for-early-detection-and-awareness-of-gastrointestinal-stromal-tumours 2026-07-16T23:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/trellis-bioscience-raises-9-million-series-c-to-advance-novel-biofilm-disrupting-antibody-for-prosthetic-joint-infections 2026-07-16T23:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trellis-bioscience-raises-9-million-series-c-to-advance-novel-biofilm-disrupting-antibody-for-prosthetic-joint-infections 2026-07-16T23:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-uncover-novel-actin-mitochondria-glutamate-pathway-driving-epilepsy-opening-new-avenues-for-genetic-diagnosis-and-treatment 2026-07-16T23:08:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-uncover-novel-actin-mitochondria-glutamate-pathway-driving-epilepsy-opening-new-avenues-for-genetic-diagnosis-and-treatment 2026-07-16T23:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/tampa-general-hospital-becomes-first-in-nation-to-sign-make-hospital-food-healthier-pledge-led-by-rfk-jr-and-michelin-star-chef 2026-07-16T23:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tampa-general-hospital-becomes-first-in-nation-to-sign-make-hospital-food-healthier-pledge-led-by-rfk-jr-and-michelin-star-chef 2026-07-16T23:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/mirador-therapeutics-licenses-kp-301-a-long-acting-anti-c5a-antibody-expanding-into-anca-associated-vasculitis 2026-07-16T23:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mirador-therapeutics-licenses-kp-301-a-long-acting-anti-c5a-antibody-expanding-into-anca-associated-vasculitis 2026-07-16T23:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/jasper-therapeutics-merges-with-kira-pharmaceuticals-secures-132-million-to-advance-complement-and-immunology-pipeline 2026-07-16T22:09:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jasper-therapeutics-merges-with-kira-pharmaceuticals-secures-132-million-to-advance-complement-and-immunology-pipeline 2026-07-16T22:09:59+00:00 hourly 0.9 https://trial.medpath.com/news/georgia-tech-launches-ai-driven-health-innovation-center-to-model-disease-at-the-cellular-level 2026-07-16T22:09:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/georgia-tech-launches-ai-driven-health-innovation-center-to-model-disease-at-the-cellular-level 2026-07-16T22:09:48+00:00 hourly 0.9 https://trial.medpath.com/news/cambridge-study-reveals-sweetener-isosteviol-combined-with-antidepressant-duloxetine-disrupts-key-gut-bacteria 2026-07-16T22:09:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cambridge-study-reveals-sweetener-isosteviol-combined-with-antidepressant-duloxetine-disrupts-key-gut-bacteria 2026-07-16T22:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/deep-origin-secures-31-7m-arpa-h-contract-to-build-fda-qualifiable-virtual-human-platform-for-drug-testing 2026-07-16T22:09:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deep-origin-secures-31-7m-arpa-h-contract-to-build-fda-qualifiable-virtual-human-platform-for-drug-testing 2026-07-16T22:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/financial-conflicts-of-interest-pervasive-across-us-cancer-ecosystem-yale-meta-analysis-finds 2026-07-16T22:08:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/financial-conflicts-of-interest-pervasive-across-us-cancer-ecosystem-yale-meta-analysis-finds 2026-07-16T22:08:59+00:00 hourly 0.9 https://trial.medpath.com/news/elizabethtown-college-and-harford-community-college-launch-2-2-biotechnology-transfer-pathway 2026-07-16T20:11:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elizabethtown-college-and-harford-community-college-launch-2-2-biotechnology-transfer-pathway 2026-07-16T20:11:27+00:00 hourly 0.9 https://trial.medpath.com/news/long-sleep-duration-linked-to-elevated-alzheimer-s-blood-biomarker-p-tau181 2026-07-16T20:10:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-sleep-duration-linked-to-elevated-alzheimer-s-blood-biomarker-p-tau181 2026-07-16T20:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/grifols-doses-first-patients-in-two-phase-3-trials-to-expand-labels-for-gamunex-c-and-xembify 2026-07-16T19:09:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grifols-doses-first-patients-in-two-phase-3-trials-to-expand-labels-for-gamunex-c-and-xembify 2026-07-16T19:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/amt-medical-s-sutureless-elana-bypass-system-meets-primary-endpoint-in-first-prospective-cabg-trial 2026-07-16T18:08:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amt-medical-s-sutureless-elana-bypass-system-meets-primary-endpoint-in-first-prospective-cabg-trial 2026-07-16T18:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-vivo-pet-evidence-reveals-widespread-m1-receptor-deficits-in-living-schizophrenia-patients 2026-07-16T18:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-vivo-pet-evidence-reveals-widespread-m1-receptor-deficits-in-living-schizophrenia-patients 2026-07-16T18:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-q2-earnings-cosentyx-and-kisqali-drive-growth-amid-entresto-decline-and-generic-pressures 2026-07-16T18:08:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-q2-earnings-cosentyx-and-kisqali-drive-growth-amid-entresto-decline-and-generic-pressures 2026-07-16T18:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/ihh-healthcare-s-futurehealth-now-2026-redefining-the-care-stack-through-ai-precision-medicine-and-value-based-care 2026-07-16T18:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ihh-healthcare-s-futurehealth-now-2026-redefining-the-care-stack-through-ai-precision-medicine-and-value-based-care 2026-07-16T18:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/definium-therapeutics-launches-wired-for-worry-initiative-to-advance-gad-education-for-healthcare-providers 2026-07-16T18:07:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/definium-therapeutics-launches-wired-for-worry-initiative-to-advance-gad-education-for-healthcare-providers 2026-07-16T18:07:53+00:00 hourly 0.9 https://trial.medpath.com/news/ent-devices-market-to-reach-usd-44-91-billion-by-2035-as-minimally-invasive-surgery-and-otc-hearing-aids-drive-growth 2026-07-16T17:09:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ent-devices-market-to-reach-usd-44-91-billion-by-2035-as-minimally-invasive-surgery-and-otc-hearing-aids-drive-growth 2026-07-16T17:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-researchers-map-multi-organ-damage-trajectories-in-hypertensive-pregnancy-to-predict-long-term-cardiovascular-risk 2026-07-16T17:08:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-researchers-map-multi-organ-damage-trajectories-in-hypertensive-pregnancy-to-predict-long-term-cardiovascular-risk 2026-07-16T17:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-expands-billion-cell-atlas-program-with-ai-native-drug-developer-formation-bio 2026-07-16T17:07:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illumina-expands-billion-cell-atlas-program-with-ai-native-drug-developer-formation-bio 2026-07-16T17:07:53+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-imaging-world-summit-2026-lafov-pet-ct-immunopet-and-theranostics-redefine-diagnostic-precision 2026-07-16T17:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-imaging-world-summit-2026-lafov-pet-ct-immunopet-and-theranostics-redefine-diagnostic-precision 2026-07-16T17:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/cryo-em-reveals-first-3d-map-of-asic1a-channel-opening-new-avenues-for-stroke-drug-development 2026-07-16T17:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cryo-em-reveals-first-3d-map-of-asic1a-channel-opening-new-avenues-for-stroke-drug-development 2026-07-16T17:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-bioepis-and-organon-expand-australian-biosimilar-partnership-to-four-products-as-pbs-default-reform-looms 2026-07-16T16:09:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-bioepis-and-organon-expand-australian-biosimilar-partnership-to-four-products-as-pbs-default-reform-looms 2026-07-16T16:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/double-neural-bypass-brain-implant-restores-movement-and-sensation-in-man-with-quadriplegia 2026-07-16T16:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/double-neural-bypass-brain-implant-restores-movement-and-sensation-in-man-with-quadriplegia 2026-07-16T16:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/gary-r-morrow-pioneer-of-cancer-supportive-care-and-symptom-management-research-dies-at-82 2026-07-16T16:09:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gary-r-morrow-pioneer-of-cancer-supportive-care-and-symptom-management-research-dies-at-82 2026-07-16T16:09:17+00:00 hourly 0.9 https://trial.medpath.com/news/drug-resistant-gonorrhoea-on-the-rise-in-europe-as-domestic-transmission-emerges-ecdc-warns 2026-07-16T16:09:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drug-resistant-gonorrhoea-on-the-rise-in-europe-as-domestic-transmission-emerges-ecdc-warns 2026-07-16T16:09:12+00:00 hourly 0.9 https://trial.medpath.com/news/nash-treatment-market-accelerates-as-rezdiffra-and-wegovy-establish-fibrosis-defined-drug-pathways 2026-07-16T16:08:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nash-treatment-market-accelerates-as-rezdiffra-and-wegovy-establish-fibrosis-defined-drug-pathways 2026-07-16T16:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-naples-federico-ii-launches-pharmatech-academy-2026-2027-for-rna-and-gene-therapy-workforce-training 2026-07-16T16:08:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-naples-federico-ii-launches-pharmatech-academy-2026-2027-for-rna-and-gene-therapy-workforce-training 2026-07-16T16:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-m72-as01e-tuberculosis-vaccine-candidate-advances-toward-global-access-with-serum-institute-of-india-manufacturing-agreement 2026-07-16T16:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-m72-as01e-tuberculosis-vaccine-candidate-advances-toward-global-access-with-serum-institute-of-india-manufacturing-agreement 2026-07-16T16:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/crown-bioscience-joins-c-path-s-nams-developer-coalition-to-advance-human-relevant-models-in-oncology-drug-development 2026-07-16T16:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crown-bioscience-joins-c-path-s-nams-developer-coalition-to-advance-human-relevant-models-in-oncology-drug-development 2026-07-16T16:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-shionogi-s-snda-for-fetroja-cefiderocol-in-pediatric-patients-with-serious-gram-negative-infections 2026-07-16T15:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-shionogi-s-snda-for-fetroja-cefiderocol-in-pediatric-patients-with-serious-gram-negative-infections 2026-07-16T15:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/ireland-defers-decision-on-skyclarys-for-friedreich-s-ataxia-amid-mounting-patient-pressure 2026-07-16T15:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ireland-defers-decision-on-skyclarys-for-friedreich-s-ataxia-amid-mounting-patient-pressure 2026-07-16T15:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/cytotoxicity-assays-market-projected-to-reach-41-2-billion-by-2034-driven-by-drug-safety-demands-and-advanced-cell-models 2026-07-16T15:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytotoxicity-assays-market-projected-to-reach-41-2-billion-by-2034-driven-by-drug-safety-demands-and-advanced-cell-models 2026-07-16T15:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/attovia-therapeutics-raises-289m-in-upsized-ipo-to-advance-biparatopic-nanobody-pipeline-in-immunology 2026-07-16T14:08:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/attovia-therapeutics-raises-289m-in-upsized-ipo-to-advance-biparatopic-nanobody-pipeline-in-immunology 2026-07-16T14:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/cryotherapeutics-treats-first-patient-in-icecap-trial-evaluating-localized-cryotherapy-for-vulnerable-coronary-plaques 2026-07-16T14:08:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cryotherapeutics-treats-first-patient-in-icecap-trial-evaluating-localized-cryotherapy-for-vulnerable-coronary-plaques 2026-07-16T14:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/shape-memory-medical-raises-10-million-to-advance-first-randomized-pivotal-trial-of-aneurysm-sac-embolization-after-evar 2026-07-16T14:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shape-memory-medical-raises-10-million-to-advance-first-randomized-pivotal-trial-of-aneurysm-sac-embolization-after-evar 2026-07-16T14:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-and-ema-accept-eisai-s-marketing-authorization-applications-for-insomnia-drug-lemborexant 2026-07-16T14:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mhra-and-ema-accept-eisai-s-marketing-authorization-applications-for-insomnia-drug-lemborexant 2026-07-16T14:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/arletta-pharma-secures-fda-endorsement-for-lybrido-phase-2-program-eyes-streamlined-path-to-nda-for-female-sexual-interest-arousal-disorder 2026-07-16T13:09:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arletta-pharma-secures-fda-endorsement-for-lybrido-phase-2-program-eyes-streamlined-path-to-nda-for-female-sexual-interest-arousal-disorder 2026-07-16T13:09:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-merck-s-oral-pcsk9-drug-a-first-in-class-cholesterol-treatment 2026-07-16T13:09:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-merck-s-oral-pcsk9-drug-a-first-in-class-cholesterol-treatment 2026-07-16T13:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/new-jersey-adopts-landmark-reforms-requiring-confirmatory-drug-testing-before-reporting-pregnant-patients-to-child-welfare 2026-07-16T13:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-jersey-adopts-landmark-reforms-requiring-confirmatory-drug-testing-before-reporting-pregnant-patients-to-child-welfare 2026-07-16T13:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/ubrigene-launches-uvivo-lentiviral-vector-platform-to-accelerate-next-generation-in-vivo-car-t-therapies 2026-07-16T13:07:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ubrigene-launches-uvivo-lentiviral-vector-platform-to-accelerate-next-generation-in-vivo-car-t-therapies 2026-07-16T13:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/telo-genomics-reports-positive-interim-data-for-3d-telomere-based-relapse-risk-assay-in-multiple-myeloma 2026-07-16T13:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telo-genomics-reports-positive-interim-data-for-3d-telomere-based-relapse-risk-assay-in-multiple-myeloma 2026-07-16T13:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/mustardseed-launches-uk-operations-to-support-life-sciences-and-advanced-manufacturing-sectors-under-britain-s-modern-industrial-strategy 2026-07-16T12:09:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mustardseed-launches-uk-operations-to-support-life-sciences-and-advanced-manufacturing-sectors-under-britain-s-modern-industrial-strategy 2026-07-16T12:09:12+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-reports-positive-12-month-data-for-once-daily-inhaled-tpip-in-pulmonary-arterial-hypertension-showing-sustained-efficacy-and-favorable-safety 2026-07-16T12:09:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insmed-reports-positive-12-month-data-for-once-daily-inhaled-tpip-in-pulmonary-arterial-hypertension-showing-sustained-efficacy-and-favorable-safety 2026-07-16T12:09:11+00:00 hourly 0.9 https://trial.medpath.com/news/synthetic-control-arms-in-hematology-generative-ai-poised-to-reshape-cancer-trial-design 2026-07-16T12:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synthetic-control-arms-in-hematology-generative-ai-poised-to-reshape-cancer-trial-design 2026-07-16T12:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/cornerstone-robotics-to-showcase-sentire-surgical-system-and-ai-driven-vision-at-global-health-summit-2026 2026-07-16T12:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cornerstone-robotics-to-showcase-sentire-surgical-system-and-ai-driven-vision-at-global-health-summit-2026 2026-07-16T12:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/4teen4-s-invobenitug-receives-fda-fast-track-designation-for-cardiogenic-shock 2026-07-16T10:14:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4teen4-s-invobenitug-receives-fda-fast-track-designation-for-cardiogenic-shock 2026-07-16T10:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/grunenthal-joins-munich-nucleic-acid-therapeutics-cluster-to-advance-oligonucleotide-based-pain-and-neurology-pipeline 2026-07-16T10:13:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grunenthal-joins-munich-nucleic-acid-therapeutics-cluster-to-advance-oligonucleotide-based-pain-and-neurology-pipeline 2026-07-16T10:13:47+00:00 hourly 0.9 https://trial.medpath.com/news/eeg-and-machine-learning-reveal-how-autistic-brains-process-faces-differently-pointing-to-new-biomarker 2026-07-16T10:13:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eeg-and-machine-learning-reveal-how-autistic-brains-process-faces-differently-pointing-to-new-biomarker 2026-07-16T10:13:01+00:00 hourly 0.9 https://trial.medpath.com/news/california-employer-health-premiums-to-hit-30000-in-2027-largest-increase-in-16-years 2026-07-16T09:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/california-employer-health-premiums-to-hit-30000-in-2027-largest-increase-in-16-years 2026-07-16T09:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/rani-therapeutics-oral-glp-1-glp-2-capsule-rt-114-achieves-bioavailability-exceeding-150-of-subcutaneous-dose-in-phase-1a-trial 2026-07-16T08:08:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rani-therapeutics-oral-glp-1-glp-2-capsule-rt-114-achieves-bioavailability-exceeding-150-of-subcutaneous-dose-in-phase-1a-trial 2026-07-16T08:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-lab-monkey-prices-surge-to-pandemic-era-highs-disrupting-drug-r-d-studies 2026-07-16T08:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-lab-monkey-prices-surge-to-pandemic-era-highs-disrupting-drug-r-d-studies 2026-07-16T08:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/delaware-biomarker-testing-bill-heads-to-governor-after-legislative-approval 2026-07-16T08:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delaware-biomarker-testing-bill-heads-to-governor-after-legislative-approval 2026-07-16T08:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/oxb-selected-as-gmp-manufacturing-partner-for-plowshare-therapies-aav-gene-therapy-programme-targeting-rare-genetic-diseases 2026-07-16T07:09:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxb-selected-as-gmp-manufacturing-partner-for-plowshare-therapies-aav-gene-therapy-programme-targeting-rare-genetic-diseases 2026-07-16T07:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/immune-cells-use-previously-unknown-tcr-dependent-mhc-independent-pathway-to-eliminate-aml 2026-07-16T07:08:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immune-cells-use-previously-unknown-tcr-dependent-mhc-independent-pathway-to-eliminate-aml 2026-07-16T07:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/persistent-racial-and-gender-inequalities-in-nhs-specialty-training-recruitment-revealed-by-national-data 2026-07-16T06:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/persistent-racial-and-gender-inequalities-in-nhs-specialty-training-recruitment-revealed-by-national-data 2026-07-16T06:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/eculizumab-induced-acute-heart-failure-decompensation-a-novel-cardiotoxic-signal-in-complement-mediated-tma 2026-07-16T05:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eculizumab-induced-acute-heart-failure-decompensation-a-novel-cardiotoxic-signal-in-complement-mediated-tma 2026-07-16T05:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/world-drowning-prevention-day-2026-who-led-global-initiative-targets-35-reduction-in-drowning-deaths-by-2035 2026-07-16T05:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-drowning-prevention-day-2026-who-led-global-initiative-targets-35-reduction-in-drowning-deaths-by-2035 2026-07-16T05:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/vvmf-and-mirugen-partner-to-advance-aav-based-gene-therapy-manufacturing-for-retinitis-pigmentosa-in-australia 2026-07-16T05:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vvmf-and-mirugen-partner-to-advance-aav-based-gene-therapy-manufacturing-for-retinitis-pigmentosa-in-australia 2026-07-16T05:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/cyclosporiasis-cases-surge-to-55-in-kansas-as-cdc-investigates-nationwide-outbreaks 2026-07-16T04:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cyclosporiasis-cases-surge-to-55-in-kansas-as-cdc-investigates-nationwide-outbreaks 2026-07-16T04:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/deaths-from-coronary-artery-disease-have-fallen-by-over-half-since-1990-yet-nearly-90-of-recent-deaths-remain-preventable 2026-07-16T04:06:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deaths-from-coronary-artery-disease-have-fallen-by-over-half-since-1990-yet-nearly-90-of-recent-deaths-remain-preventable 2026-07-16T04:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/whiddon-college-of-medicine-hosts-53rd-annual-medical-student-research-day-with-69-student-researchers 2026-07-16T04:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/whiddon-college-of-medicine-hosts-53rd-annual-medical-student-research-day-with-69-student-researchers 2026-07-16T04:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/new-york-state-health-department-issues-mosquito-borne-disease-alert-as-west-nile-virus-detected-in-three-counties 2026-07-16T03:06:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-york-state-health-department-issues-mosquito-borne-disease-alert-as-west-nile-virus-detected-in-three-counties 2026-07-16T03:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/telix-opens-australia-s-first-integrated-radiopharmaceutical-facility-to-accelerate-cancer-theranostics 2026-07-16T03:06:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telix-opens-australia-s-first-integrated-radiopharmaceutical-facility-to-accelerate-cancer-theranostics 2026-07-16T03:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/loneliness-linked-to-poorer-mental-and-general-health-distinct-from-social-isolation-triangulation-study-finds 2026-07-16T02:09:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/loneliness-linked-to-poorer-mental-and-general-health-distinct-from-social-isolation-triangulation-study-finds 2026-07-16T02:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/cdd-vault-user-group-meeting-brings-drug-discovery-professionals-together-in-boston 2026-07-16T01:07:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdd-vault-user-group-meeting-brings-drug-discovery-professionals-together-in-boston 2026-07-16T01:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/emergent-vibrio-parahaemolyticus-gastroenteritis-outbreaks-in-new-zealand-2019-2022-trans-pacific-spread-of-st36-and-emergence-of-st50 2026-07-16T00:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emergent-vibrio-parahaemolyticus-gastroenteritis-outbreaks-in-new-zealand-2019-2022-trans-pacific-spread-of-st36-and-emergence-of-st50 2026-07-16T00:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/shy-therapeutics-doses-first-patient-in-phase-i-trial-of-novel-19s-proteasome-inhibitor-shy-onc6-for-solid-tumors 2026-07-16T00:07:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shy-therapeutics-doses-first-patient-in-phase-i-trial-of-novel-19s-proteasome-inhibitor-shy-onc6-for-solid-tumors 2026-07-16T00:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/mississippi-joins-29-6-million-multistate-settlement-with-glenmark-over-generic-drug-price-fixing-allegations 2026-07-15T23:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mississippi-joins-29-6-million-multistate-settlement-with-glenmark-over-generic-drug-price-fixing-allegations 2026-07-15T23:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/nih-launches-population-genomic-screening-network-to-bring-preventative-genomics-into-primary-care 2026-07-15T22:12:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-launches-population-genomic-screening-network-to-bring-preventative-genomics-into-primary-care 2026-07-15T22:12:15+00:00 hourly 0.9 https://trial.medpath.com/news/study-narrows-list-of-genetic-suspects-behind-adolescent-idiopathic-scoliosis 2026-07-15T22:11:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-narrows-list-of-genetic-suspects-behind-adolescent-idiopathic-scoliosis 2026-07-15T22:11:32+00:00 hourly 0.9 https://trial.medpath.com/news/vietnam-s-pharma-market-set-to-top-10-billion-by-2026-amid-regulatory-reforms-and-demographic-shifts 2026-07-15T22:11:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vietnam-s-pharma-market-set-to-top-10-billion-by-2026-amid-regulatory-reforms-and-demographic-shifts 2026-07-15T22:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/telangana-merges-food-safety-and-drugs-control-departments-into-unified-regulatory-body-tg-safe 2026-07-15T20:14:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telangana-merges-food-safety-and-drugs-control-departments-into-unified-regulatory-body-tg-safe 2026-07-15T20:14:58+00:00 hourly 0.9 https://trial.medpath.com/news/aladynoulli-a-bayesian-generative-model-integrates-ehr-and-genetic-data-to-outperform-clinical-risk-scores-in-disease-prediction 2026-07-15T20:14:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aladynoulli-a-bayesian-generative-model-integrates-ehr-and-genetic-data-to-outperform-clinical-risk-scores-in-disease-prediction 2026-07-15T20:14:54+00:00 hourly 0.9 https://trial.medpath.com/news/retraction-count-for-anesthesiologist-joachim-boldt-reaches-240-as-journals-continue-purging-fraudulent-papers 2026-07-15T20:14:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/retraction-count-for-anesthesiologist-joachim-boldt-reaches-240-as-journals-continue-purging-fraudulent-papers 2026-07-15T20:14:38+00:00 hourly 0.9 https://trial.medpath.com/news/ai-tool-aladynoulli-predicts-risk-of-348-diseases-from-routine-health-records-outperforming-existing-risk-models 2026-07-15T20:14:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-tool-aladynoulli-predicts-risk-of-348-diseases-from-routine-health-records-outperforming-existing-risk-models 2026-07-15T20:14:34+00:00 hourly 0.9 https://trial.medpath.com/news/how-epstein-barr-virus-triggers-immune-response-in-multiple-sclerosis-new-mechanistic-insights 2026-07-15T20:13:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-epstein-barr-virus-triggers-immune-response-in-multiple-sclerosis-new-mechanistic-insights 2026-07-15T20:13:57+00:00 hourly 0.9 https://trial.medpath.com/news/bipartisan-bill-seeks-to-streamline-fda-biosimilar-approvals-expand-access-to-lower-cost-biologics 2026-07-15T20:13:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bipartisan-bill-seeks-to-streamline-fda-biosimilar-approvals-expand-access-to-lower-cost-biologics 2026-07-15T20:13:55+00:00 hourly 0.9 https://trial.medpath.com/news/thyme-care-raises-125-million-valuation-tops-2-billion-as-it-expands-beyond-navigation 2026-07-15T20:13:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thyme-care-raises-125-million-valuation-tops-2-billion-as-it-expands-beyond-navigation 2026-07-15T20:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/pepmd-launches-to-establish-credentialing-and-trust-standards-for-peptide-medicine 2026-07-15T20:12:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pepmd-launches-to-establish-credentialing-and-trust-standards-for-peptide-medicine 2026-07-15T20:12:22+00:00 hourly 0.9 https://trial.medpath.com/news/cumberland-pharmaceuticals-ifetroban-advances-across-multiple-rare-disease-indications 2026-07-15T20:11:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cumberland-pharmaceuticals-ifetroban-advances-across-multiple-rare-disease-indications 2026-07-15T20:11:31+00:00 hourly 0.9 https://trial.medpath.com/news/bipartisan-bill-seeks-to-streamline-biosimilar-approvals-lower-prescription-drug-costs 2026-07-15T20:11:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bipartisan-bill-seeks-to-streamline-biosimilar-approvals-lower-prescription-drug-costs 2026-07-15T20:11:29+00:00 hourly 0.9 https://trial.medpath.com/news/sinopia-biosciences-sb-0110-shows-preclinical-promise-in-boosting-l-dopa-efficacy-while-reducing-dyskinesia-in-parkinson-s-disease 2026-07-15T19:10:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sinopia-biosciences-sb-0110-shows-preclinical-promise-in-boosting-l-dopa-efficacy-while-reducing-dyskinesia-in-parkinson-s-disease 2026-07-15T19:10:02+00:00 hourly 0.9 https://trial.medpath.com/news/illinois-advances-breakthrough-psychedelic-therapies-for-veteran-suicide-prevention-through-new-legislation 2026-07-15T19:09:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illinois-advances-breakthrough-psychedelic-therapies-for-veteran-suicide-prevention-through-new-legislation 2026-07-15T19:09:32+00:00 hourly 0.9 https://trial.medpath.com/news/advancell-raises-record-450-million-to-advance-lead-212-alpha-therapy-into-phase-iii-for-prostate-cancer 2026-07-15T19:09:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancell-raises-record-450-million-to-advance-lead-212-alpha-therapy-into-phase-iii-for-prostate-cancer 2026-07-15T19:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/nature-portfolio-opens-submissions-for-macrophages-in-cancer-collection 2026-07-15T19:09:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nature-portfolio-opens-submissions-for-macrophages-in-cancer-collection 2026-07-15T19:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/fast-02-trial-shows-proton-flash-radiotherapy-delivers-75-complete-pain-relief-for-thoracic-bone-metastases-with-no-serious-adverse-events 2026-07-15T18:07:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fast-02-trial-shows-proton-flash-radiotherapy-delivers-75-complete-pain-relief-for-thoracic-bone-metastases-with-no-serious-adverse-events 2026-07-15T18:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/global-childhood-immunization-rates-stall-at-90-dtp-coverage-13-5-million-children-remain-zero-dose-in-2025 2026-07-15T18:07:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-childhood-immunization-rates-stall-at-90-dtp-coverage-13-5-million-children-remain-zero-dose-in-2025 2026-07-15T18:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/anova-and-nouveau-biosciences-partner-to-advance-first-in-human-trial-of-nanomedicine-kromastat-for-t-cell-lymphomas 2026-07-15T18:06:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anova-and-nouveau-biosciences-partner-to-advance-first-in-human-trial-of-nanomedicine-kromastat-for-t-cell-lymphomas 2026-07-15T18:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-launches-up-to-750-million-pharmaceutical-supply-chain-restructuring-exiting-select-manufacturing-sites 2026-07-15T18:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-launches-up-to-750-million-pharmaceutical-supply-chain-restructuring-exiting-select-manufacturing-sites 2026-07-15T18:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-beats-q2-estimates-raises-full-year-2026-guidance-on-strong-pharmaceutical-sales 2026-07-15T17:07:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-beats-q2-estimates-raises-full-year-2026-guidance-on-strong-pharmaceutical-sales 2026-07-15T17:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-director-nominee-erica-schwartz-affirms-support-for-mrna-vaccines-in-senate-confirmation-hearing 2026-07-15T17:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-director-nominee-erica-schwartz-affirms-support-for-mrna-vaccines-in-senate-confirmation-hearing 2026-07-15T17:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/leading-women-s-health-organizations-launch-national-strategy-to-close-the-women-s-health-gap-calling-for-20-billion-congressional-investment 2026-07-15T16:13:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leading-women-s-health-organizations-launch-national-strategy-to-close-the-women-s-health-gap-calling-for-20-billion-congressional-investment 2026-07-15T16:13:11+00:00 hourly 0.9 https://trial.medpath.com/news/adlm-2026-to-showcase-breakthroughs-in-diabetes-space-medicine-alzheimer-s-down-syndrome-link-and-cancer-diagnostics 2026-07-15T16:12:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adlm-2026-to-showcase-breakthroughs-in-diabetes-space-medicine-alzheimer-s-down-syndrome-link-and-cancer-diagnostics 2026-07-15T16:12:38+00:00 hourly 0.9 https://trial.medpath.com/news/dyne-therapeutics-nears-first-commercial-launch-with-z-rostudirsen-pdufa-set-for-january-21-in-duchenne-muscular-dystrophy 2026-07-15T16:12:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyne-therapeutics-nears-first-commercial-launch-with-z-rostudirsen-pdufa-set-for-january-21-in-duchenne-muscular-dystrophy 2026-07-15T16:12:36+00:00 hourly 0.9 https://trial.medpath.com/news/texas-children-s-physician-scientist-wins-700000-burroughs-wellcome-fund-award-to-uncover-genetic-drivers-of-rare-immune-disorders 2026-07-15T16:11:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/texas-children-s-physician-scientist-wins-700000-burroughs-wellcome-fund-award-to-uncover-genetic-drivers-of-rare-immune-disorders 2026-07-15T16:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1b-trial-shows-short-lived-anti-pd-l1-antibody-ibc-ab002-is-well-tolerated-in-early-alzheimer-s-disease 2026-07-15T16:11:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1b-trial-shows-short-lived-anti-pd-l1-antibody-ibc-ab002-is-well-tolerated-in-early-alzheimer-s-disease 2026-07-15T16:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/fighting-data-fragmentation-emerges-as-the-next-frontier-for-life-sciences-innovation 2026-07-15T16:11:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fighting-data-fragmentation-emerges-as-the-next-frontier-for-life-sciences-innovation 2026-07-15T16:11:08+00:00 hourly 0.9 https://trial.medpath.com/news/septa-pharmaceuticals-acquires-ceenu-lomustine-from-bristol-myers-squibb-canada-strengthening-oncology-portfolio 2026-07-15T16:09:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/septa-pharmaceuticals-acquires-ceenu-lomustine-from-bristol-myers-squibb-canada-strengthening-oncology-portfolio 2026-07-15T16:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/allogeneic-car-t-cell-therapy-allo-316-demonstrates-durable-responses-in-advanced-clear-cell-renal-cell-carcinoma 2026-07-15T16:09:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allogeneic-car-t-cell-therapy-allo-316-demonstrates-durable-responses-in-advanced-clear-cell-renal-cell-carcinoma 2026-07-15T16:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/maxona-pharmaceuticals-receives-fda-ind-clearance-for-max-001-phase-2-acute-pain-trial 2026-07-15T16:08:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maxona-pharmaceuticals-receives-fda-ind-clearance-for-max-001-phase-2-acute-pain-trial 2026-07-15T16:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/optimaize-ai-driven-closed-loop-platform-aims-to-accelerate-antibiotic-development-against-multidrug-resistant-bacteria 2026-07-15T16:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/optimaize-ai-driven-closed-loop-platform-aims-to-accelerate-antibiotic-development-against-multidrug-resistant-bacteria 2026-07-15T16:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/nutrafol-study-demonstrates-19-37-faster-hair-growth-in-women-using-multi-targeting-nutraceuticals 2026-07-15T16:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nutrafol-study-demonstrates-19-37-faster-hair-growth-in-women-using-multi-targeting-nutraceuticals 2026-07-15T16:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/new-therapeutic-targets-and-immunotherapy-approaches-emerge-for-cerebral-small-vessel-disease 2026-07-15T16:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-therapeutic-targets-and-immunotherapy-approaches-emerge-for-cerebral-small-vessel-disease 2026-07-15T16:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/wearable-microneedle-patches-move-toward-real-time-closed-loop-drug-monitoring 2026-07-15T16:07:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wearable-microneedle-patches-move-toward-real-time-closed-loop-drug-monitoring 2026-07-15T16:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/bambusa-therapeutics-appoints-howard-liang-to-board-establishes-scientific-advisory-board-to-guide-bispecific-antibody-pipeline 2026-07-15T16:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bambusa-therapeutics-appoints-howard-liang-to-board-establishes-scientific-advisory-board-to-guide-bispecific-antibody-pipeline 2026-07-15T16:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/latent-labs-launches-latent-y-first-lab-validated-ai-drug-design-agent-to-researchers-worldwide 2026-07-15T16:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/latent-labs-launches-latent-y-first-lab-validated-ai-drug-design-agent-to-researchers-worldwide 2026-07-15T16:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-strengthens-safety-warnings-for-botulinum-toxin-type-a-products-following-rare-cases-of-iatrogenic-botulism 2026-07-15T15:07:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mhra-strengthens-safety-warnings-for-botulinum-toxin-type-a-products-following-rare-cases-of-iatrogenic-botulism 2026-07-15T15:07:53+00:00 hourly 0.9 https://trial.medpath.com/news/orasis-pharmaceuticals-and-aspen-submit-new-drug-application-in-australia-for-beska-pilocarpine-hcl-0-4-for-presbyopia 2026-07-15T15:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orasis-pharmaceuticals-and-aspen-submit-new-drug-application-in-australia-for-beska-pilocarpine-hcl-0-4-for-presbyopia 2026-07-15T15:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/florida-cancer-specialists-research-institute-appoints-dr-amanda-olson-as-medical-director-of-late-phase-research 2026-07-15T15:07:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/florida-cancer-specialists-research-institute-appoints-dr-amanda-olson-as-medical-director-of-late-phase-research 2026-07-15T15:07:47+00:00 hourly 0.9 https://trial.medpath.com/news/neurothera-labs-initiates-phase-iib-trial-of-cannabinoid-based-sci-110-for-tourette-syndrome-at-hannover-medical-school 2026-07-15T14:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurothera-labs-initiates-phase-iib-trial-of-cannabinoid-based-sci-110-for-tourette-syndrome-at-hannover-medical-school 2026-07-15T14:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-identifies-three-new-murine-models-for-mpox-reveals-2022-clade-iib-is-up-to-100000-fold-less-virulent-than-2003-clade-iia 2026-07-15T14:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-identifies-three-new-murine-models-for-mpox-reveals-2022-clade-iib-is-up-to-100000-fold-less-virulent-than-2003-clade-iia 2026-07-15T14:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/kairos-pharma-reports-zero-grade-3-toxicities-in-phase-1-trial-of-env-105-for-egfr-mutated-lung-cancer 2026-07-15T14:06:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kairos-pharma-reports-zero-grade-3-toxicities-in-phase-1-trial-of-env-105-for-egfr-mutated-lung-cancer 2026-07-15T14:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/fgfr-inhibitor-cancer-drugs-linked-to-dry-eye-and-corneal-damage-in-faers-analysis 2026-07-15T13:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fgfr-inhibitor-cancer-drugs-linked-to-dry-eye-and-corneal-damage-in-faers-analysis 2026-07-15T13:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/nmpa-clears-ind-for-hbm7575-skb575-a-long-acting-tslp-bispecific-antibody-for-asthma 2026-07-15T12:08:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nmpa-clears-ind-for-hbm7575-skb575-a-long-acting-tslp-bispecific-antibody-for-asthma 2026-07-15T12:08:56+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-study-reveals-elevated-risk-of-rare-inherited-diseases-in-scottish-traveller-founder-population 2026-07-15T12:08:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-study-reveals-elevated-risk-of-rare-inherited-diseases-in-scottish-traveller-founder-population 2026-07-15T12:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/gw-rhythmx-launches-rhythmx-pulse-on-microsoft-marketplace-integrating-precision-care-ai-with-dragon-copilot 2026-07-15T12:08:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gw-rhythmx-launches-rhythmx-pulse-on-microsoft-marketplace-integrating-precision-care-ai-with-dragon-copilot 2026-07-15T12:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/lemon-frost-gecko-emerges-as-promising-natural-model-for-human-cancer-research 2026-07-15T12:07:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lemon-frost-gecko-emerges-as-promising-natural-model-for-human-cancer-research 2026-07-15T12:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/recell-go-demonstrates-successful-first-clinical-use-in-uk-burn-surgery-supporting-global-adoption-of-automated-autologous-cell-therapy 2026-07-15T12:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recell-go-demonstrates-successful-first-clinical-use-in-uk-burn-surgery-supporting-global-adoption-of-automated-autologous-cell-therapy 2026-07-15T12:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/simris-biologics-appoints-adc-expert-professor-andreas-pahl-as-ceo-to-advance-microcystin-payload-platform 2026-07-15T11:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simris-biologics-appoints-adc-expert-professor-andreas-pahl-as-ceo-to-advance-microcystin-payload-platform 2026-07-15T11:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/nbj-summit-2026-announces-keynote-lineup-ai-driven-healthcare-biohacking-and-leadership-take-center-stage 2026-07-15T11:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nbj-summit-2026-announces-keynote-lineup-ai-driven-healthcare-biohacking-and-leadership-take-center-stage 2026-07-15T11:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/mapping-the-tumor-microenvironment-immune-pathway-signatures-predict-immunotherapy-outcomes-in-melanoma 2026-07-15T10:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mapping-the-tumor-microenvironment-immune-pathway-signatures-predict-immunotherapy-outcomes-in-melanoma 2026-07-15T10:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-trontinemab-enters-landmark-trial-to-prevent-alzheimer-s-before-symptoms-emerge 2026-07-15T10:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-trontinemab-enters-landmark-trial-to-prevent-alzheimer-s-before-symptoms-emerge 2026-07-15T10:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/england-on-track-to-eliminate-hepatitis-c-ahead-of-who-2030-target-following-nhs-drug-deal-and-targeted-screening 2026-07-15T10:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/england-on-track-to-eliminate-hepatitis-c-ahead-of-who-2030-target-following-nhs-drug-deal-and-targeted-screening 2026-07-15T10:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/bangladesh-drug-pricing-deadlock-stalls-hundreds-of-new-medicines-threatens-industry-innovation 2026-07-15T10:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bangladesh-drug-pricing-deadlock-stalls-hundreds-of-new-medicines-threatens-industry-innovation 2026-07-15T10:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/59-of-clinical-trial-sites-losing-eligible-patients-to-process-inefficiencies-survey-reveals 2026-07-15T10:06:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/59-of-clinical-trial-sites-losing-eligible-patients-to-process-inefficiencies-survey-reveals 2026-07-15T10:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-files-countersuit-against-curevac-in-ongoing-covid-19-mrna-vaccine-patent-dispute 2026-07-15T09:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-files-countersuit-against-curevac-in-ongoing-covid-19-mrna-vaccine-patent-dispute 2026-07-15T09:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/ai-accelerates-cancer-drug-discovery-sk-telecom-and-sk-biopharmaceuticals-identify-ror1-targeting-compounds-in-five-months 2026-07-15T09:06:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-accelerates-cancer-drug-discovery-sk-telecom-and-sk-biopharmaceuticals-identify-ror1-targeting-compounds-in-five-months 2026-07-15T09:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/permanent-daylight-saving-time-vs-standard-time-what-the-science-says-about-health-impacts 2026-07-15T08:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/permanent-daylight-saving-time-vs-standard-time-what-the-science-says-about-health-impacts 2026-07-15T08:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/egfr-tkis-pose-highest-cardiovascular-risk-among-tyrosine-kinase-inhibitors-meta-analysis-finds 2026-07-15T08:09:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/egfr-tkis-pose-highest-cardiovascular-risk-among-tyrosine-kinase-inhibitors-meta-analysis-finds 2026-07-15T08:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/billiontoone-to-report-second-quarter-2026-financial-results-on-august-5-2026 2026-07-15T08:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/billiontoone-to-report-second-quarter-2026-financial-results-on-august-5-2026 2026-07-15T08:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-reshuffles-leadership-bouye-to-head-generics-manufacturing-haruvi-adds-global-m-a-oversight 2026-07-15T07:10:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandoz-reshuffles-leadership-bouye-to-head-generics-manufacturing-haruvi-adds-global-m-a-oversight 2026-07-15T07:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/judge-tosses-vanda-s-fight-against-fda-s-drug-approval-structure 2026-07-15T07:10:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/judge-tosses-vanda-s-fight-against-fda-s-drug-approval-structure 2026-07-15T07:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/tissue-resident-macrophages-emerge-as-master-regulators-of-aging-through-ep2-driven-neutrophil-clearance 2026-07-15T07:09:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tissue-resident-macrophages-emerge-as-master-regulators-of-aging-through-ep2-driven-neutrophil-clearance 2026-07-15T07:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/guided-therapeutics-advances-china-expansion-with-new-distribution-agreement-and-purchase-order-payments-for-luviva-cervical-scan 2026-07-15T07:09:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guided-therapeutics-advances-china-expansion-with-new-distribution-agreement-and-purchase-order-payments-for-luviva-cervical-scan 2026-07-15T07:09:17+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-pharmaceuticals-ai-driven-drug-discovery-platform-faces-pipeline-validation-hurdles-amid-mixed-analyst-sentiment 2026-07-15T07:09:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-pharmaceuticals-ai-driven-drug-discovery-platform-faces-pipeline-validation-hurdles-amid-mixed-analyst-sentiment 2026-07-15T07:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/south-korea-s-mfds-advances-formal-regulatory-framework-for-cell-cultured-processed-foods 2026-07-15T06:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-korea-s-mfds-advances-formal-regulatory-framework-for-cell-cultured-processed-foods 2026-07-15T06:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/gem-commits-up-to-nt-500-million-to-senhwa-biosciences-to-advance-oncology-pipeline 2026-07-15T06:07:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gem-commits-up-to-nt-500-million-to-senhwa-biosciences-to-advance-oncology-pipeline 2026-07-15T06:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/lytac-therapy-targets-root-cause-of-diabetic-foot-ulcers-by-removing-excess-inflammatory-proteins 2026-07-15T04:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lytac-therapy-targets-root-cause-of-diabetic-foot-ulcers-by-removing-excess-inflammatory-proteins 2026-07-15T04:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/cancervax-unveils-polyepitope-smart-mrna-platform-that-disguises-cancer-as-multiple-viral-infections-achieving-99-5-global-population-coverage 2026-07-15T04:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancervax-unveils-polyepitope-smart-mrna-platform-that-disguises-cancer-as-multiple-viral-infections-achieving-99-5-global-population-coverage 2026-07-15T04:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/rts-s-malaria-vaccine-shows-early-impact-in-cameroon-but-fourth-dose-drop-off-threatens-durability-of-protection 2026-07-15T01:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rts-s-malaria-vaccine-shows-early-impact-in-cameroon-but-fourth-dose-drop-off-threatens-durability-of-protection 2026-07-15T01:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/alabama-state-university-and-callan-jmb-forge-landmark-partnership-to-transform-marion-into-a-national-pharmaceutical-manufacturing-hub 2026-07-15T01:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alabama-state-university-and-callan-jmb-forge-landmark-partnership-to-transform-marion-into-a-national-pharmaceutical-manufacturing-hub 2026-07-15T01:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/snmmi-and-pcf-award-600000-to-young-investigators-advancing-next-generation-radiopharmaceutical-and-combination-therapies-for-prostate-cancer 2026-07-15T01:06:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/snmmi-and-pcf-award-600000-to-young-investigators-advancing-next-generation-radiopharmaceutical-and-combination-therapies-for-prostate-cancer 2026-07-15T01:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-microenvironment-ecotypes-may-explain-differences-in-multiple-myeloma-outcomes 2026-07-15T01:06:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tumor-microenvironment-ecotypes-may-explain-differences-in-multiple-myeloma-outcomes 2026-07-15T01:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/hudsonalpha-s-bridges-engine-secures-up-to-160-million-nsf-award-to-build-rural-bioeconomy-in-alabama-and-tennessee 2026-07-15T01:06:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hudsonalpha-s-bridges-engine-secures-up-to-160-million-nsf-award-to-build-rural-bioeconomy-in-alabama-and-tennessee 2026-07-15T01:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/full-spectrum-cannabis-oil-linked-to-improved-quality-of-life-and-sleep-satisfaction-in-medical-marijuana-patients 2026-07-15T01:06:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/full-spectrum-cannabis-oil-linked-to-improved-quality-of-life-and-sleep-satisfaction-in-medical-marijuana-patients 2026-07-15T01:06:22+00:00 hourly 0.9 https://trial.medpath.com/news/mri-linac-adoption-expands-as-centers-report-real-time-precision-radiation-therapy 2026-07-14T23:07:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mri-linac-adoption-expands-as-centers-report-real-time-precision-radiation-therapy 2026-07-14T23:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-abandons-rule-to-withhold-medicare-and-medicaid-funding-over-pediatric-gender-affirming-care 2026-07-14T22:09:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-abandons-rule-to-withhold-medicare-and-medicaid-funding-over-pediatric-gender-affirming-care 2026-07-14T22:09:11+00:00 hourly 0.9 https://trial.medpath.com/news/hawley-walks-out-of-senate-patent-hearing-after-clash-over-drug-prices-and-pera-legislation 2026-07-14T22:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hawley-walks-out-of-senate-patent-hearing-after-clash-over-drug-prices-and-pera-legislation 2026-07-14T22:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/environmental-testing-begins-in-ladera-ranch-after-rare-childhood-cancer-cluster-concerns 2026-07-14T21:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/environmental-testing-begins-in-ladera-ranch-after-rare-childhood-cancer-cluster-concerns 2026-07-14T21:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/boostimmune-secures-japanese-patent-for-tctp-targeting-antibody-technology-to-advance-cancer-immunotherapy 2026-07-14T21:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boostimmune-secures-japanese-patent-for-tctp-targeting-antibody-technology-to-advance-cancer-immunotherapy 2026-07-14T21:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/high-q-technologies-deploys-quantum-epr-sensors-to-accelerate-drug-discovery-for-alzheimer-s-and-neurodegenerative-diseases 2026-07-14T20:13:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-q-technologies-deploys-quantum-epr-sensors-to-accelerate-drug-discovery-for-alzheimer-s-and-neurodegenerative-diseases 2026-07-14T20:13:21+00:00 hourly 0.9 https://trial.medpath.com/news/global-review-identifies-11-high-potential-preclinical-candidates-for-preeclampsia-exposing-gaps-in-evidence-quality-and-therapeutic-diversity 2026-07-14T20:13:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-review-identifies-11-high-potential-preclinical-candidates-for-preeclampsia-exposing-gaps-in-evidence-quality-and-therapeutic-diversity 2026-07-14T20:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/ftc-secures-landmark-settlement-with-cvs-caremark-to-reshape-pbm-business-practices-and-lower-drug-costs 2026-07-14T20:12:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ftc-secures-landmark-settlement-with-cvs-caremark-to-reshape-pbm-business-practices-and-lower-drug-costs 2026-07-14T20:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-vaccines-plus-checkpoint-inhibitors-proposed-as-a-new-therapeutic-frontier-for-endometriosis 2026-07-14T20:12:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-vaccines-plus-checkpoint-inhibitors-proposed-as-a-new-therapeutic-frontier-for-endometriosis 2026-07-14T20:12:48+00:00 hourly 0.9 https://trial.medpath.com/news/milky-white-blood-in-infant-reveals-ultra-rare-familial-lipoprotein-lipase-deficiency 2026-07-14T20:12:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/milky-white-blood-in-infant-reveals-ultra-rare-familial-lipoprotein-lipase-deficiency 2026-07-14T20:12:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-replimune-s-twice-rejected-melanoma-viral-therapy-tudriqev-after-white-house-intervention 2026-07-14T20:11:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-replimune-s-twice-rejected-melanoma-viral-therapy-tudriqev-after-white-house-intervention 2026-07-14T20:11:43+00:00 hourly 0.9 https://trial.medpath.com/news/ark-invest-exits-biontech-position-amid-revenue-decline-and-leadership-transition 2026-07-14T20:10:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ark-invest-exits-biontech-position-amid-revenue-decline-and-leadership-transition 2026-07-14T20:10:58+00:00 hourly 0.9 https://trial.medpath.com/news/marchesini-group-to-showcase-pharma-and-aseptic-packaging-innovations-at-cphi-2026-in-milan 2026-07-14T20:10:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marchesini-group-to-showcase-pharma-and-aseptic-packaging-innovations-at-cphi-2026-in-milan 2026-07-14T20:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/roswell-park-showcases-ai-powered-oral-cancer-detection-platform-and-precision-advances-at-ahns-2026 2026-07-14T20:10:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roswell-park-showcases-ai-powered-oral-cancer-detection-platform-and-precision-advances-at-ahns-2026 2026-07-14T20:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-braces-for-uneventful-q2-as-investors-eye-pivotal-melanoma-vaccine-data-in-2026 2026-07-14T19:08:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-braces-for-uneventful-q2-as-investors-eye-pivotal-melanoma-vaccine-data-in-2026 2026-07-14T19:08:49+00:00 hourly 0.9 https://trial.medpath.com/news/south-african-researcher-awarded-r3m-grant-to-advance-trop2-targeted-theranostics-for-breast-cancer 2026-07-14T19:08:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-african-researcher-awarded-r3m-grant-to-advance-trop2-targeted-theranostics-for-breast-cancer 2026-07-14T19:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/avere-therapeutics-to-go-public-via-nextcure-merger-secures-320-million-to-advance-once-weekly-oral-il-23-antagonist-for-psoriasis 2026-07-14T18:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avere-therapeutics-to-go-public-via-nextcure-merger-secures-320-million-to-advance-once-weekly-oral-il-23-antagonist-for-psoriasis 2026-07-14T18:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/geneseeq-canada-named-first-genomic-testing-partner-in-uhn-s-sherlock-study-a-7000-patient-prospective-cancer-genomics-platform 2026-07-14T18:07:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geneseeq-canada-named-first-genomic-testing-partner-in-uhn-s-sherlock-study-a-7000-patient-prospective-cancer-genomics-platform 2026-07-14T18:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/nucleome-therapeutics-secures-us-patent-for-micro-capture-c-3d-genomics-platform-advancing-first-in-class-inflammatory-disease-pipeline 2026-07-14T18:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nucleome-therapeutics-secures-us-patent-for-micro-capture-c-3d-genomics-platform-advancing-first-in-class-inflammatory-disease-pipeline 2026-07-14T18:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/american-red-cross-declares-emergency-blood-shortage-as-supply-drops-to-crisis-levels 2026-07-14T17:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/american-red-cross-declares-emergency-blood-shortage-as-supply-drops-to-crisis-levels 2026-07-14T17:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/alport-syndrome-market-projected-to-surge-at-47-cagr-through-2036-fueled-by-emerging-disease-modifying-therapies 2026-07-14T17:10:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alport-syndrome-market-projected-to-surge-at-47-cagr-through-2036-fueled-by-emerging-disease-modifying-therapies 2026-07-14T17:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/influenza-b-triggers-earlier-more-robust-immune-response-than-influenza-a-study-finds 2026-07-14T17:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/influenza-b-triggers-earlier-more-robust-immune-response-than-influenza-a-study-finds 2026-07-14T17:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/exosomes-as-early-biomarkers-for-diabetes-tiny-vesicles-may-reveal-disease-before-symptoms-emerge 2026-07-14T17:08:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exosomes-as-early-biomarkers-for-diabetes-tiny-vesicles-may-reveal-disease-before-symptoms-emerge 2026-07-14T17:08:17+00:00 hourly 0.9 https://trial.medpath.com/news/acrobiosystems-secures-pmda-material-suitability-confirmation-for-gmp-grade-il-15-streamlining-cell-therapy-approvals-in-japan 2026-07-14T17:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acrobiosystems-secures-pmda-material-suitability-confirmation-for-gmp-grade-il-15-streamlining-cell-therapy-approvals-in-japan 2026-07-14T17:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-desiccants-market-projected-to-reach-565-78-million-by-2035-driven-by-pharmaceutical-and-biologics-packaging-demand 2026-07-14T17:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-desiccants-market-projected-to-reach-565-78-million-by-2035-driven-by-pharmaceutical-and-biologics-packaging-demand 2026-07-14T17:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/lyora-therapeutics-launches-with-2-5m-seed-funding-to-advance-genetic-medicines-for-inherited-retinal-diseases 2026-07-14T17:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lyora-therapeutics-launches-with-2-5m-seed-funding-to-advance-genetic-medicines-for-inherited-retinal-diseases 2026-07-14T17:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/the-technology-is-ready-are-apac-s-regulators-continuous-manufacturing-faces-a-standoff-in-asia-pacific 2026-07-14T16:10:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-technology-is-ready-are-apac-s-regulators-continuous-manufacturing-faces-a-standoff-in-asia-pacific 2026-07-14T16:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/innopharm-2026-to-convene-global-pharmaceutical-r-d-leaders-in-boston 2026-07-14T16:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innopharm-2026-to-convene-global-pharmaceutical-r-d-leaders-in-boston 2026-07-14T16:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/global-vaccine-sales-market-to-reach-us-141-40-billion-by-2036-as-next-generation-platforms-accelerate-growth 2026-07-14T16:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-vaccine-sales-market-to-reach-us-141-40-billion-by-2036-as-next-generation-platforms-accelerate-growth 2026-07-14T16:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/immunobrain-s-anti-pd-l1-antibody-ibc-ab002-shows-early-biomarker-signal-in-phase-1b-alzheimer-s-trial-published-in-nature-medicine 2026-07-14T16:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunobrain-s-anti-pd-l1-antibody-ibc-ab002-shows-early-biomarker-signal-in-phase-1b-alzheimer-s-trial-published-in-nature-medicine 2026-07-14T16:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/masked-t-cell-engagers-and-pasritamig-raise-new-hope-for-advanced-prostate-cancer-immunotherapy 2026-07-14T16:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/masked-t-cell-engagers-and-pasritamig-raise-new-hope-for-advanced-prostate-cancer-immunotherapy 2026-07-14T16:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/medunik-canada-secures-exclusive-distribution-rights-for-increlex-r-mecasermin-in-canada-bolstering-access-for-children-with-severe-primary-igf-1-deficiency 2026-07-14T16:07:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medunik-canada-secures-exclusive-distribution-rights-for-increlex-r-mecasermin-in-canada-bolstering-access-for-children-with-severe-primary-igf-1-deficiency 2026-07-14T16:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/applied-biologics-manufactures-first-research-construct-for-disease-modifying-osteoarthritis-gene-therapy 2026-07-14T16:06:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/applied-biologics-manufactures-first-research-construct-for-disease-modifying-osteoarthritis-gene-therapy 2026-07-14T16:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/umass-amherst-secures-2-1-million-for-advanced-optical-tweezers-and-micro-patterning-systems-to-accelerate-drug-discovery 2026-07-14T16:06:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/umass-amherst-secures-2-1-million-for-advanced-optical-tweezers-and-micro-patterning-systems-to-accelerate-drug-discovery 2026-07-14T16:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-visionary-john-f-crowley-to-keynote-emily-whitehead-foundation-s-2026-believe-ball-in-philadelphia 2026-07-14T15:06:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-visionary-john-f-crowley-to-keynote-emily-whitehead-foundation-s-2026-believe-ball-in-philadelphia 2026-07-14T15:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-s-voluntary-mfn-drug-pricing-agreements-reshape-strategy-at-pfizer-abbvie-and-bristol-myers-squibb 2026-07-14T15:06:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-s-voluntary-mfn-drug-pricing-agreements-reshape-strategy-at-pfizer-abbvie-and-bristol-myers-squibb 2026-07-14T15:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/lexitas-and-ocusun-launch-pilot-study-of-lanosterol-derived-eye-drop-for-age-related-cataract 2026-07-14T15:06:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexitas-and-ocusun-launch-pilot-study-of-lanosterol-derived-eye-drop-for-age-related-cataract 2026-07-14T15:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/sleep-habits-may-modify-how-aqp4-gene-variants-shape-early-alzheimer-s-brain-changes 2026-07-14T14:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sleep-habits-may-modify-how-aqp4-gene-variants-shape-early-alzheimer-s-brain-changes 2026-07-14T14:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/mytomorrows-survey-reveals-52-of-clinical-trial-sites-say-1-in-5-referrals-are-ineligible-before-screening-even-begins 2026-07-14T14:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mytomorrows-survey-reveals-52-of-clinical-trial-sites-say-1-in-5-referrals-are-ineligible-before-screening-even-begins 2026-07-14T14:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/supernus-marks-five-years-of-qelbree-the-first-novel-non-stimulant-adhd-treatment-in-over-a-decade 2026-07-14T14:07:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supernus-marks-five-years-of-qelbree-the-first-novel-non-stimulant-adhd-treatment-in-over-a-decade 2026-07-14T14:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/inductive-bio-wins-third-consecutive-ai-drug-discovery-benchmark-topping-350-competitors-in-pxr-blind-challenge 2026-07-14T14:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inductive-bio-wins-third-consecutive-ai-drug-discovery-benchmark-topping-350-competitors-in-pxr-blind-challenge 2026-07-14T14:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/new-drug-rso-021-shows-promise-in-mesothelioma-trial-by-targeting-cancer-s-energy-system 2026-07-14T14:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-drug-rso-021-shows-promise-in-mesothelioma-trial-by-targeting-cancer-s-energy-system 2026-07-14T14:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/huyabio-s-hbi-8000-plus-nivolumab-delivers-58-improvement-in-progression-free-survival-in-phase-3-advanced-melanoma-trial 2026-07-14T14:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huyabio-s-hbi-8000-plus-nivolumab-delivers-58-improvement-in-progression-free-survival-in-phase-3-advanced-melanoma-trial 2026-07-14T14:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/laboratory-operations-innovator-chris-clendening-joins-precision-for-medicine-to-lead-global-specialty-labs 2026-07-14T14:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/laboratory-operations-innovator-chris-clendening-joins-precision-for-medicine-to-lead-global-specialty-labs 2026-07-14T14:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/epilepsygtx-partners-with-clearpoint-neuro-for-precision-delivery-of-gene-therapy-epy201-in-focal-refractory-epilepsy-trial 2026-07-14T14:06:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epilepsygtx-partners-with-clearpoint-neuro-for-precision-delivery-of-gene-therapy-epy201-in-focal-refractory-epilepsy-trial 2026-07-14T14:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/skinmedica-deepens-regenerative-science-commitment-with-advisory-board-launch-r-d-expansion-and-flagship-retail-debut 2026-07-14T13:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/skinmedica-deepens-regenerative-science-commitment-with-advisory-board-launch-r-d-expansion-and-flagship-retail-debut 2026-07-14T13:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/atrium-therapeutics-secures-fda-clearance-of-ind-for-atr-1072-first-disease-modifying-therapy-for-prkag2-syndrome 2026-07-14T13:06:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atrium-therapeutics-secures-fda-clearance-of-ind-for-atr-1072-first-disease-modifying-therapy-for-prkag2-syndrome 2026-07-14T13:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/summit-therapeutics-sells-phase-iii-antibiotic-ridinilazole-to-ai-native-biossil-in-deal-worth-up-to-104-5-million 2026-07-14T13:06:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/summit-therapeutics-sells-phase-iii-antibiotic-ridinilazole-to-ai-native-biossil-in-deal-worth-up-to-104-5-million 2026-07-14T13:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/evonik-invests-100-million-to-modernize-indiana-api-manufacturing-facility-expanding-u-s-cdmo-capabilities 2026-07-14T12:10:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evonik-invests-100-million-to-modernize-indiana-api-manufacturing-facility-expanding-u-s-cdmo-capabilities 2026-07-14T12:10:48+00:00 hourly 0.9 https://trial.medpath.com/news/spero-therapeutics-secures-105-million-non-dilutive-royalty-financing-to-advance-anti-cd40l-antibody-sp001 2026-07-14T12:09:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spero-therapeutics-secures-105-million-non-dilutive-royalty-financing-to-advance-anti-cd40l-antibody-sp001 2026-07-14T12:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-and-spero-strike-1-1-billion-deal-for-third-generation-anti-cd40l-antibody-targeting-igg4-rd-and-sjogren-s-disease 2026-07-14T12:09:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-and-spero-strike-1-1-billion-deal-for-third-generation-anti-cd40l-antibody-targeting-igg4-rd-and-sjogren-s-disease 2026-07-14T12:09:08+00:00 hourly 0.9 https://trial.medpath.com/news/late-stage-ckd-therapeutics-market-projected-to-reach-25-2-billion-by-2032-driven-by-integrated-cardio-renal-strategies-and-emerging-biologics 2026-07-14T11:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/late-stage-ckd-therapeutics-market-projected-to-reach-25-2-billion-by-2032-driven-by-integrated-cardio-renal-strategies-and-emerging-biologics 2026-07-14T11:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/annexon-perfect-complement-to-a-speculative-biotech-portfolio 2026-07-14T11:09:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/annexon-perfect-complement-to-a-speculative-biotech-portfolio 2026-07-14T11:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/draig-therapeutics-secures-65m-series-b-to-advance-dt-101-phase-2-trials-in-major-depressive-disorder 2026-07-14T11:08:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/draig-therapeutics-secures-65m-series-b-to-advance-dt-101-phase-2-trials-in-major-depressive-disorder 2026-07-14T11:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/physiomics-director-ian-bagnall-increases-stake-with-ps5000-share-purchase 2026-07-14T09:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/physiomics-director-ian-bagnall-increases-stake-with-ps5000-share-purchase 2026-07-14T09:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/pervasive-gene-environment-interactions-reshape-polygenic-risk-score-utility-across-exposures 2026-07-14T09:07:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pervasive-gene-environment-interactions-reshape-polygenic-risk-score-utility-across-exposures 2026-07-14T09:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/iluvien-meets-both-co-primary-endpoints-in-phase-4-synchronicity-trial-for-chronic-non-infectious-uveitis 2026-07-14T09:07:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iluvien-meets-both-co-primary-endpoints-in-phase-4-synchronicity-trial-for-chronic-non-infectious-uveitis 2026-07-14T09:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/myotonia-may-amplify-muscle-damage-in-myotonic-dystrophy-type-1-new-study-reveals 2026-07-14T08:09:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myotonia-may-amplify-muscle-damage-in-myotonic-dystrophy-type-1-new-study-reveals 2026-07-14T08:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/roche-launches-first-fully-automated-hepatitis-d-virus-diagnostic-test-addressing-critical-unmet-need 2026-07-14T07:09:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-launches-first-fully-automated-hepatitis-d-virus-diagnostic-test-addressing-critical-unmet-need 2026-07-14T07:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-grants-quia-timet-injunction-barring-intas-from-launching-novartis-patented-dabrafenib 2026-07-14T07:09:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delhi-high-court-grants-quia-timet-injunction-barring-intas-from-launching-novartis-patented-dabrafenib 2026-07-14T07:09:06+00:00 hourly 0.9 https://trial.medpath.com/news/foundation-for-sarcoidosis-research-launches-groundbreaking-clinical-data-registry-across-13-leading-us-institutions 2026-07-14T06:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foundation-for-sarcoidosis-research-launches-groundbreaking-clinical-data-registry-across-13-leading-us-institutions 2026-07-14T06:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-eye-imaging-models-accelerate-ophthalmic-clinical-trial-recruitment-and-drug-development 2026-07-14T06:10:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-eye-imaging-models-accelerate-ophthalmic-clinical-trial-recruitment-and-drug-development 2026-07-14T06:10:39+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-therapeutics-and-vertex-s-casgevy-first-regulatory-approved-cell-based-gene-therapy-for-sickle-cell-disease-and-beta-thalassemia 2026-07-14T04:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-therapeutics-and-vertex-s-casgevy-first-regulatory-approved-cell-based-gene-therapy-for-sickle-cell-disease-and-beta-thalassemia 2026-07-14T04:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/brazil-weighs-patent-term-adjustment-legislation-as-pharmaceutical-innovation-faces-uncertainty 2026-07-14T02:09:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brazil-weighs-patent-term-adjustment-legislation-as-pharmaceutical-innovation-faces-uncertainty 2026-07-14T02:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/ireland-s-orphan-drug-access-crisis-reimbursement-delays-leave-rare-disease-patients-waiting-years 2026-07-14T02:09:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ireland-s-orphan-drug-access-crisis-reimbursement-delays-leave-rare-disease-patients-waiting-years 2026-07-14T02:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/nearly-6-in-10-young-women-get-health-information-from-influencers-pew-survey-finds 2026-07-14T01:08:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nearly-6-in-10-young-women-get-health-information-from-influencers-pew-survey-finds 2026-07-14T01:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-jcog1403-trial-single-dose-intravesical-pirarubicin-cuts-bladder-recurrence-after-nephroureterectomy 2026-07-14T00:10:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-jcog1403-trial-single-dose-intravesical-pirarubicin-cuts-bladder-recurrence-after-nephroureterectomy 2026-07-14T00:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-finalizes-guidance-on-formal-meetings-with-drug-and-biologics-sponsors 2026-07-13T22:12:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-finalizes-guidance-on-formal-meetings-with-drug-and-biologics-sponsors 2026-07-13T22:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/blood-based-biomarker-tests-poised-to-transform-alzheimer-s-diagnosis-in-primary-care 2026-07-13T22:11:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-based-biomarker-tests-poised-to-transform-alzheimer-s-diagnosis-in-primary-care 2026-07-13T22:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/protect-our-care-launches-national-sick-of-it-fix-health-care-now-campaign-across-nine-states 2026-07-13T22:10:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protect-our-care-launches-national-sick-of-it-fix-health-care-now-campaign-across-nine-states 2026-07-13T22:10:54+00:00 hourly 0.9 https://trial.medpath.com/news/targeted-therapies-transform-stage-4-lung-cancer-from-death-sentence-to-chronic-condition 2026-07-13T22:10:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/targeted-therapies-transform-stage-4-lung-cancer-from-death-sentence-to-chronic-condition 2026-07-13T22:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/cu-anschutz-school-of-medicine-welcomes-class-of-2030-at-annual-matriculation-ceremony 2026-07-13T21:09:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cu-anschutz-school-of-medicine-welcomes-class-of-2030-at-annual-matriculation-ceremony 2026-07-13T21:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/electronic-symptom-monitoring-reduces-disparities-in-advanced-cancer-care-pro-tect-trial-shows 2026-07-13T19:14:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/electronic-symptom-monitoring-reduces-disparities-in-advanced-cancer-care-pro-tect-trial-shows 2026-07-13T19:14:22+00:00 hourly 0.9 https://trial.medpath.com/news/prolonged-spaceflight-linked-to-female-reproductive-dysfunction-and-transgenerational-effects-in-landmark-mouse-study 2026-07-13T19:14:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prolonged-spaceflight-linked-to-female-reproductive-dysfunction-and-transgenerational-effects-in-landmark-mouse-study 2026-07-13T19:14:14+00:00 hourly 0.9 https://trial.medpath.com/news/wvu-medicine-wetzel-county-hospital-expands-outpatient-infusion-center-to-seven-day-service 2026-07-13T19:14:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wvu-medicine-wetzel-county-hospital-expands-outpatient-infusion-center-to-seven-day-service 2026-07-13T19:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/epigenetic-therapy-ntx-301-activates-hippo-pathway-to-overcome-treatment-resistant-aml 2026-07-13T19:12:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epigenetic-therapy-ntx-301-activates-hippo-pathway-to-overcome-treatment-resistant-aml 2026-07-13T19:12:02+00:00 hourly 0.9 https://trial.medpath.com/news/single-molecule-imaging-reveals-how-copper-imbalance-may-drive-alzheimer-s-parkinson-s-and-als 2026-07-13T19:11:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-molecule-imaging-reveals-how-copper-imbalance-may-drive-alzheimer-s-parkinson-s-and-als 2026-07-13T19:11:29+00:00 hourly 0.9 https://trial.medpath.com/news/genome-scale-crispri-atlas-maps-gene-function-across-2-5-million-human-ipscs 2026-07-13T17:13:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genome-scale-crispri-atlas-maps-gene-function-across-2-5-million-human-ipscs 2026-07-13T17:13:22+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-the-pill-rna-interference-aldosterone-synthase-inhibition-and-incretins-reshape-hypertension-drug-development 2026-07-13T17:13:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyond-the-pill-rna-interference-aldosterone-synthase-inhibition-and-incretins-reshape-hypertension-drug-development 2026-07-13T17:13:06+00:00 hourly 0.9 https://trial.medpath.com/news/federated-learning-gains-momentum-in-drug-discovery-as-pharma-giants-and-biotechs-build-collaborative-ai-networks 2026-07-13T17:13:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federated-learning-gains-momentum-in-drug-discovery-as-pharma-giants-and-biotechs-build-collaborative-ai-networks 2026-07-13T17:13:01+00:00 hourly 0.9 https://trial.medpath.com/news/periscope-ii-gastrectomy-cytoreductive-surgery-and-hipec-do-not-improve-survival-in-gastric-cancer-with-limited-peritoneal-metastases 2026-07-13T17:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/periscope-ii-gastrectomy-cytoreductive-surgery-and-hipec-do-not-improve-survival-in-gastric-cancer-with-limited-peritoneal-metastases 2026-07-13T17:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/enovis-launches-next-generation-ct-revitl-veterinary-laser-therapy-system-in-the-u-s 2026-07-13T17:10:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enovis-launches-next-generation-ct-revitl-veterinary-laser-therapy-system-in-the-u-s 2026-07-13T17:10:58+00:00 hourly 0.9 https://trial.medpath.com/news/uk-locks-pharma-patent-protections-into-swiss-trade-deal-sparking-nhs-cost-concerns 2026-07-13T17:09:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-locks-pharma-patent-protections-into-swiss-trade-deal-sparking-nhs-cost-concerns 2026-07-13T17:09:55+00:00 hourly 0.9 https://trial.medpath.com/news/oliceridine-demonstrates-non-inferior-analgesia-and-superior-safety-vs-sufentanil-in-post-cesarean-pcia 2026-07-13T17:09:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oliceridine-demonstrates-non-inferior-analgesia-and-superior-safety-vs-sufentanil-in-post-cesarean-pcia 2026-07-13T17:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/alzheimer-s-survivor-82-embarks-on-650-mile-walk-across-england-to-demonstrate-potential-of-precision-medicine-protocol 2026-07-13T16:08:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzheimer-s-survivor-82-embarks-on-650-mile-walk-across-england-to-demonstrate-potential-of-precision-medicine-protocol 2026-07-13T16:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-treated-in-phase-2-a-tango-trial-evaluating-yaqrit-s-tlr4-antagonist-yaq005-for-acute-on-chronic-liver-failure 2026-07-13T15:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-treated-in-phase-2-a-tango-trial-evaluating-yaqrit-s-tlr4-antagonist-yaq005-for-acute-on-chronic-liver-failure 2026-07-13T15:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/alzheimer-s-research-leaders-highlight-fda-approved-therapies-blood-biomarkers-and-prevention-strategies-at-date-with-a-cure-2026 2026-07-13T15:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzheimer-s-research-leaders-highlight-fda-approved-therapies-blood-biomarkers-and-prevention-strategies-at-date-with-a-cure-2026 2026-07-13T15:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/military-handheld-blood-test-device-i-stat-alinity-deployed-to-middle-east-for-rapid-tbi-diagnosis-in-15-minutes 2026-07-13T15:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/military-handheld-blood-test-device-i-stat-alinity-deployed-to-middle-east-for-rapid-tbi-diagnosis-in-15-minutes 2026-07-13T15:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/spine-surgery-s-new-bottleneck-data-infrastructure-not-the-operating-room 2026-07-13T14:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spine-surgery-s-new-bottleneck-data-infrastructure-not-the-operating-room 2026-07-13T14:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/delonix-bioworks-doses-first-participant-in-china-phase-1-trial-of-next-generation-menb-omv-vaccine-dx-104 2026-07-13T14:11:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delonix-bioworks-doses-first-participant-in-china-phase-1-trial-of-next-generation-menb-omv-vaccine-dx-104 2026-07-13T14:11:38+00:00 hourly 0.9 https://trial.medpath.com/news/decentralized-clinical-trials-gain-momentum-in-nutraceutical-sector-as-regulatory-scrutiny-intensifies 2026-07-13T14:11:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/decentralized-clinical-trials-gain-momentum-in-nutraceutical-sector-as-regulatory-scrutiny-intensifies 2026-07-13T14:11:29+00:00 hourly 0.9 https://trial.medpath.com/news/bright-minds-biosciences-to-present-5-ht2-agonist-pipeline-at-upcoming-investor-conferences 2026-07-13T14:10:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bright-minds-biosciences-to-present-5-ht2-agonist-pipeline-at-upcoming-investor-conferences 2026-07-13T14:10:55+00:00 hourly 0.9 https://trial.medpath.com/news/survey-finds-strong-majority-support-for-vet-supervised-biomedical-animal-research-in-the-u-s 2026-07-13T14:10:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/survey-finds-strong-majority-support-for-vet-supervised-biomedical-animal-research-in-the-u-s 2026-07-13T14:10:51+00:00 hourly 0.9 https://trial.medpath.com/news/xtalks-webinar-to-explore-how-patient-perceptions-of-normalcy-and-identity-drive-clinical-trial-recruitment-decisions 2026-07-13T14:10:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xtalks-webinar-to-explore-how-patient-perceptions-of-normalcy-and-identity-drive-clinical-trial-recruitment-decisions 2026-07-13T14:10:34+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-microenvironment-responsive-prodrugs-emerge-as-a-strategy-to-overcome-hcc-treatment-barriers 2026-07-13T14:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tumor-microenvironment-responsive-prodrugs-emerge-as-a-strategy-to-overcome-hcc-treatment-barriers 2026-07-13T14:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/kim-v-narry-becomes-first-korean-and-asian-recipient-of-hfsp-nakasone-award-for-pioneering-mrna-tail-research 2026-07-13T13:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kim-v-narry-becomes-first-korean-and-asian-recipient-of-hfsp-nakasone-award-for-pioneering-mrna-tail-research 2026-07-13T13:08:24+00:00 hourly 0.9